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Psychometric Evaluation of the Chemotherapy Induced Peripheral Neuropathy 
Assessment Tool
Cindy Tofthagen
ABSTRACT
Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of 
several chemotherapy drugs used for the treatment of many common malignancies. CIPN 
is both under-assessed and underreported and few self-report tools exist that measure 
CIPN. Existing instruments do not evaluate all of the multi-dimensional characteristics of 
neuropathic symptoms; intensity, distress, timing, and characteristics. The purpose of this
descriptive, cross-sectional study was to develop and psychometrically evaluate a new 
self - report tool for CIPN, the Chemotherapy Induced Peripheral Neuropathy 
Assessment Tool (CIPNAT).  Interviews with 15 patients with known CIPN guided 
development of the CIPNAT. 
The CIPNAT is a 69 item self-report tool which measures CIPN, including 
characteristics, intensity, distress, frequency, and interference with usual activities.
Content validity was evaluated by a panel of experts and revisions were made to the 
CIPNAT based on those results. The CIPNAT was administered to 167 patients on 
chemotherapy at H. Lee Moffitt Cancer Center and a two physician medical oncology 
practice in Tampa, Florida. The Functional Assessment of Cancer Therapy-Neurotoxicity 
scale (FACT/GOG-Ntx), another self-report tool for CIPN was also administered. 
vii
Correlations between the CIPNAT and the FACT/GOG-Ntx  were evaluated. Differences 
between a group of 40 patients getting non-neurotoxic chemotherapy and a group of 127 
patients getting neurotoxic chemotherapy were also examined. Test-retest reliability was 
evaluated by administering the CIPNAT a second time to a subgroup of 30 patients and 
correlating the results. Correlation with a measure of the same concept indicated that 
scores between the CIPNAT and the FACT-Ntx were strong (r =.73, p=.000, 
n=127).Differences between the two contrasting groups were significant (p = .000), 
supporting validity. High test-retest correlations (r =.921, p=.000) demonstrated 
reliability. Cronbach’s alpha for the total CIPNAT (alpha=.945), the symptom experience 
scale (alpha =.927) and the interference scale (alpha=.897) demonstrated high internal 
consistency reliability. Confirmatory factor analysis of neuropathic symptoms indicated 
the presence of two underlying factors, sensory symptoms and motor symptoms. 
Confirmatory factor analysis of the interference scale also indicated two underlying 
factors, activities requiring manual dexterity and general activities. These results provide
strong evidence of the validity and reliability of the CIPNAT. 
1Chapter One
Introduction
Chemotherapy induced peripheral neuropathy  (CIPN)  is a group of 
neuromuscular symptoms that result from nerve damage caused by drug therapies used in 
the treatment of cancer (Visovsky, 2003). Peripheral neuropathies are one of the most 
frequently occurring and distressing side effects of chemotherapy (Visovsky, 2003; 
Wickham, 2007).  More than 30% of patients who receive paclitaxel, docetaxel, 
bortezomib, thalidomide, or oxaliplatin will develop chemotherapy induced peripheral 
neuropathy (CIPN).  Several other drugs commonly used in the fight against cancer cause 
CIPN in 10-29% of patients (University of Florida Shands Cancer Center, 2007).  The 
development of new anticancer therapies has led to increased survival (American Cancer 
Society, 2008); but several of these new therapies are toxic to the nervous system, 
causing a variety of unpleasant symptoms that are uncomfortable and difficult to manage 
(Bakitas, 2007; Wilkes, 2007). Severe peripheral neuropathies result in dose reductions, a 
change in chemotherapy regimen, or early cessation of chemotherapy, all of which 
compromise the success of cancer treatment (Mantyh, 2006). In addition, neuropathies 
can interfere with key aspects of quality of life including physical, social, and role 
functioning and emotional well being (Bakitas, 2007; Ostchega, Donohue, & Fox, 1988).
2Underlying Mechanisms
The mechanisms that cause CIPN are not well understood. Large diameter 
neurons are surrounded by an insulating layer, or myelin sheath, and are called either A-
alpha fibers or A-beta fibers (Kasper et al., 2005). The myelin sheath helps facilitate 
transmission of impulses along the nerve. Smaller diameter neurons are called C fibers or 
A-delta fibers and lack a myelin sheath (Kasper et al., 2005). Many chemotherapy agents 
are believed to cause destruction or dysfunction of the myelin sheath. This may cause 
abnormal burning, prickling, or tingling sensations called paresthesias. Loss of vibratory 
sense, two-point discrimination, and proprioception may also result from damage to the 
myelin sheath (Mantyh, 2006). Destruction or dysfunction of C and A-delta fibers results 
in muscle pain, burning pain in the extremities, and increased sensitivity to cold. Damage 
to the nervous system is believed to cause sensitization and hyperexcitability of 
peripheral nociceptors and hyperexcitability of the dorsal horn (Baron, 2006). Severe and 
irreversible sensory neuropathies can be the result of axonal degeneration and injury to 
the dorsal root ganglion and are associated with neurotoxic chemotherapies such as 
cisplatin, paclitaxel, and oxaliplatin (Ocean & Vahdat, 2004).  
Risk Factors and Symptoms
The biggest risk factor for the development of CIPN is treatment with neurotoxic 
anti-cancer drugs (Ostchega et al., 1988; Visovsky, C, 2003; Wickham, 2007; Wilkes, 
2007).  Risk of developing CIPN rises as the cumulative dose of chemotherapy escalates 
(Lipton et al., 1989; Pietrangeli, Leandri, Terzoli, Jandolo, & Garufi, 2006; Quasthoff & 
Hartung, 2002). People who receive two or more neurotoxic chemotherapy drugs are at 
3higher  risk  as are those with preexisting neuropathy (Badros et al., 2007; Chaudhry, 
Chaudhry, Crawford, Simmons-O'Brien, & Griffin, 2003; Gordon, Stringer, Matthews, 
Willis, & Nemunaitis, 1997; Huang, Brady, Cella, & Fleming, 2007).
Symptoms of CIPN may include numbness and/or tingling beginning in the tips of 
the fingers or toes ( Ocean & Vahdat, 2004; Wilkes, 2007). Burning, shooting, or electric 
like pain, prickling sensation, loss of touch and temperature discrimination, hyporeflexia, 
and muscle weakness also are reported. Symptoms become more pronounced with 
escalating doses of the drug, frequently resulting in discontinuation of the drug before 
maximum benefit is achieved (Dunlap & Paice, 2006). Although symptoms usually 
subside when the neurotoxic drug is stopped, permanent damage to the nervous system 
can occur (Ocean & Vahdat, 2004).  CIPN is associated with decreased ability to perform 
activities of daily living, psychological distress and reduced satisfaction with life 
(Ostchega, Donohue, & Fox, 1988).
Neuropathies can be categorized as either sensory or motor symptoms (Quasthoff 
& Hartung, 2002). Motor symptoms affect skeletal muscles. Motor symptoms include 
arthralgias, myalgias, muscle weakness, and loss of balance. Sensory nerves affect 
sensation and provide information about touch, pain, temperature, vibration and position 
(Sweeney, 2002). Sensory symptoms may include numbness, tingling, neuropathic pain, 
and sensitivity to cold or heat.
Neuropathic symptoms can also be classified as painful  or non-painful (Empl et 
al., 2001) . Painful symptoms involve exaggerated or unusual sensations while non-
painful symptoms involve loss of sensation (Kasper et al., 2005). Other authors have used 
4the terms positive and negative (Kasper et al., 2005), ataxic and painful, and painful and 
painless (Uceyler, Rogausch, Toyka, & Sommer, 2007) to similarly classify neuropathic 
symptoms. 
Definition of Terms
Chemotherapy induced peripheral neuropathy. Chemotherapy induced peripheral 
neuropathy refers to a group of neuromuscular symptoms that result from nerve damage 
caused by drug therapies used in the treatment of cancer (Visovsky, 2003). 
Manifestations of chemotherapy induced peripheral neuropathy include painful 
neuropathic symptoms, non-painful neuropathic symptoms, and interference with usual 
activities. 
Painful neuropathy. Painful neuropathy refers to a group of neurological 
symptoms characterized by pain, discomfort, or exaggerated sensation. Painful 
neuropathy also can be referred to as neuropathic pain (Backonja, 2003). The 
International Association for the Study of Pain (IASP) defines neuropathic pain as “pain 
initiated or caused by a primary lesion or dysfunction of the nervous system”(Merskey & 
Bogduk, 1994, p.209-214). Painful neuropathy can be described using a variety of terms 
including sharp, tingling, aching, burning, shooting, or electric-like but not all patients 
with CIPN identify uncomfortable neurologic symptoms as painful (Smith, Whedon, & 
Bookbinder, 2002).
Non-painful neuropathy. Non-painful neuropathy refers to a group of neurological 
symptoms characterized by loss of sensation or loss of function. Numbness, muscle 
weakness, loss of deep tendon reflexes, loss of balance, and loss of fine motor skills are 
5all examples of non-painful neuropathy. Non-painful neuropathy is thought to  have a 
greater  effect on physical function than painful neuropathy (Empl et al., 2001). 
Symptom interference. Symptom interference with usual activity refers to the 
extent to which symptoms interfere with activities that are necessary to meet basic needs 
and maintain health and well-being (Leidy, 1994). CIPN  symptoms are believed to have 
a negative impact on patients’ ability to perform their usual activities by negatively 
affecting physical performance (Almadrones, McGuire, Walczak, Florio, & Tian, 2004; 
Bakitas, 2007; Smith et al., 2002; Visovsky, 2003). Physical performance is an important 
aspect of quality of life for individuals with cancer (Ferreira et al., 2008).
Measurement
Lack of a “gold standard” assessment technique, inconsistent use of terminology, 
lack of psychometric evidence to support the use of self-report instruments in cancer 
populations, and lack of attention to multidimensional characteristics are some of the 
limitations associated with CIPN (Dunlap & Paice, 2006). Comprehensive assessment of 
CIPN is a critical step toward the development of interventions to promote safety, 
alleviate symptoms, and maximize quality of life for persons with cancer. Two general 
approaches to assessment are discussed in the existing literature. One approach is 
clinician evaluation, and the second approach is patient self-report.
Clinical evaluation. Clinician evaluation is accomplished through complete 
neurologic examination, nerve conduction studies, and the use of grading scales. 
Assessment via complete neurological exam and nerve conduction studies can yield 
useful information; however results of such testing often do not correlate with patient 
6report and do not adequately portray the symptom experience (Calhoun et al., 2003). 
Grading scales often are used in research and practice.  The World Health Organization, 
Eastern Cooperative Oncology Group and National Cancer Institute all have developed 
grading scales for CIPN (Oncology Nursing Society, 2005). Scores for these scales are 
calculated by clinicians based on patient report and physical exam. Grading scales, while 
useful, have many limitations including their uni-dimensional nature and lack of 
sensitivity and specificity (Wickham, 2007).                 
Performance measures designed to help clinicians assess neuropathic symptoms 
have been developed, including the Total Neuropathy Score, the Neuropathy Symptom 
Profile, and the Neurological Disability Score.  Results of these scales can be subjective, 
dependent upon the expertise of the examiner and only address prevalence of symptoms. 
They do not provide information on severity, distress, timing, or impact on daily 
activities (Postma et al., 2005).
Self-report. Self-report is a critical element of evaluation of CIPN. Few reliable 
and valid instruments for CIPN are currently available. Existing instruments, though well 
designed and psychometrically sound, do not capture the multidimensional experience of 
CIPN. Some instruments assess neuropathic pain but are not specific to chemotherapy 
induced peripheral neuropathy. Others do not include evaluation of non-painful 
symptoms or motor symptoms. Most of these instruments measure the presence of 
symptoms, attempt to evaluate physical dysfunction related to neuropathies, and some 
also assess quality of life, but none of the instruments assess intensity, timing, or distress 
caused by CIPN. Furthermore, their assessment of symptom interference is not 
7comprehensive enough to give clinicians and researchers enough information to guide 
clinical decision making. A more detailed evaluation of individual symptoms and 
symptom interference would provide more information to help clinicians suggest 
interventions designed to maximize patient safety and physical performance. It would 
also allow researchers to evaluate the efficacy of such interventions. The challenge in 
developing a more comprehensive self report tool for CIPN is to make it brief and easy to 
administer (Dunlap & Paice, 2006). 
A detailed discussion of the psychometric properties of the instruments available for 
CIPN follows in the review of literature.
Statement of the Problem and Purpose
Researchers interested in studying chemotherapy induced peripheral neuropathy 
need more scientifically validated measurement tools. Several tools have been developed 
but many measurement issues still exist in the study of CIPN including lack of a “gold 
standard” assessment technique, lack of psychometric evidence to support the use of self-
report instruments in cancer populations, and lack of attention to the multidimensional 
characteristics of CIPN (Dunlap & Paice, 2006).
The purpose of the study is to evaluate the psychometric properties of an 
instrument designed to measure CIPN, the Chemotherapy Induced Peripheral Neuropathy 
Assessment Tool (CIPNAT) (Appendix B). Assessment of symptoms included presence 
of neuropathic symptoms, intensity, distress, timing of symptoms, and impact of 
symptoms on daily activities. Psychometric evaluation included assessment of content 
validity, construct validity, test-retest reliability, and internal consistency reliability. 
8Development and testing of this instrument was conducted in three phases. Phase 
I was a mixed methods analysis of interviews with 15 patients with CIPN. The methods 
and quantitative results are discussed in Chapter Three. Phase II involved having a panel 
of five experts review the content of the CIPNAT and provide feedback on the relevance 
of each item. Revisions to the CIPNAT were made based on feedback from the panel of 
experts. Phase II methods and results are discussed in Chapter Four. Phase III involved 
administering the CIPNAT to a group of patients in order to evaluate its reliability and 
validity in cancer patients receiving chemotherapy. Phase III methods and results are 
discussed in Chapter Five.
Conceptual Framework
The conceptual framework for this study is based upon the Theory of Unpleasant 
Symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; Lenz, Suppe, Gift, Pugh, & 
Milligan, 1995). Physical, psychological, and social factors all influence the symptom 
experience. The physical factors that influence neuropathic symptoms include 
chemotherapy drug used, the treatment schedule, and the cumulative dose (Lenz, et al., 
1997) (Figure 1). The authors conceptualized unpleasant symptoms like CIPN to be 
multidimensional in nature (Lenz, et al., 1997).  Character, timing, intensity, and distress
are important aspects of the symptom experience, and evaluation of these dimensions will 
lead to a better understanding of meaningful aspects of CIPN. 
Characteristics. Characteristics of CIPN vary from person to person and are 
influenced in part by which chemotherapy drug patients receive. Patients may experience 
one or more neuropathic symptoms at the same time and may develop more neuropathic 
9symptoms over time. The presence of more neuropathic symptoms indicates more severe 
CIPN. 
Figure 1. Conceptual framework based on Theory of Unpleasant Symptoms.
Timing. Timing of neuropathic symptoms includes the time of day symptoms 
occur or are most severe, whether symptoms are intermittent or continuous, and whether 
they are most severe following chemotherapy. Certain neuropathic symptoms are more 
likely to be continuous. Numbness and generalized weakness are conceptualized as 
gradually progressing over time but once they occur, these symptoms are likely to be 
continuous. Other symptoms like pain, cold sensitivity, and arthralgias/myalgias may be 
Physical Factors
drug, schedule,
cumulative dose 
Characteristics 
sensitivity to cold.
Numbness, muscle weakness, 
generalized weakness, loss of 
balance.
Intensity
How severe is it?
Timing 
How often does it occur?
Time of day.
Is it worst following chemo?
Physical 
Performance
How much do 
symptoms 
interfere with
activities?
Distress
How much does it bother you?
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more likely to occur in the days following chemotherapy. Continuous symptoms may 
signify more severe neuropathy than intermittent symptoms. 
Intensity. Intensity refers to how severe patients perceive their symptoms and may 
be useful in evaluating changes in symptoms over time. It is possible for two people to 
report the same level of intensity but have very different levels of distress. More severe 
individual symptoms contribute to higher levels of CIPN but alone do not provide enough 
information to assess overall severity of neuropathic symptoms.
Distress. Distress is an emotional component of the symptom experience. It 
signifies how emotionally troubled someone is by the symptoms they are experiencing. 
Many factors can influence distress level such as other life stressors, competing demands, 
and limited physical performance. For example, a man who plays an instrument for a 
living who finds he is gradually losing the manual dexterity needed to play his instrument 
will probably experience more distress over numbness in the hands than he will from 
numbness in the feet. Another individual who enjoys running but is now experiencing 
numbness in the feet may be more bothered by that symptom. 
Physical performance. Character, intensity, distress and timing should be included 
in assessment of CIPN because these elements influence physical performance. 
Neuropathic influence on physical performance can be assessed by evaluating to what 
extent the ability to participate in usual activities has been affected by neuropathic 
symptoms. It also is important to determine which activities may be adversely affected 
because when physical performance is impaired, it may threaten patients’ independence 
and negatively influence self-concept. 
11
Significance to Nursing
Nurses are instrumental in providing symptom management to oncology patients 
(Smith et al., 2002). Well designed instruments should help nurses more thoroughly 
assess symptoms. Adequate assessment is critical in planning nursing interventions to 
best meet the needs of the patient. Psychometrically sound measurement tools that better 
capture the full experience of patients are needed. Currently, there are no instruments for 
CIPN that evaluate character, intensity, distress, timing, and impact on physical 
functioning. Development of such an instrument would allow clinicians and researchers 
to thoroughly evaluate the impact of peripheral neuropathies on physical and emotional 
outcomes. More detailed evaluation of CIPN will help nurses and other health care 
professionals design and implement interventions to help prevent symptoms, recognize 
symptoms earlier, and treat symptoms more effectively. 
12
Chapter Two
Review of the Literature
Subjective measures may provide more useful information regarding symptoms 
than physical exam (Calhoun, et al., 2003). A few self-report tools have been developed 
to help quantify symptoms of CIPN. They are useful for quantifying the presence of 
neuropathic symptoms but do not adequately assess emotional distress caused by 
neuropathic symptoms, timing of symptoms, or effects of symptoms on physical function. 
Studies evaluating the psychometric properties of existing instruments are discussed in 
the remainder of this chapter.
Peripheral Neuropathy Scale
Ostchega, Donohue, and Fox (1988) were the first nurse researchers to design a self 
report tool to assess CIPN and describe the affects of CIPN on daily functioning. Using a 
modified version of the European Organization for Treatment of Cancer Quality of Life 
Questionnaire (EORTC QOLQ) they devised an instrument intended to reflect common 
complaints associated with CIPN (Figure 2).  The Peripheral Neuropathy Scale (PNS) 
consisted of five items evaluating the presence of numbness, tingling, pain, and stiffness 
or tightness in the hands and feet and three items addressing physical function. A four 
point rating system included possible responses of not at all = 1, a little = 2, quite a bit = 
3, and very much = 4. Content validity for the PNS was evaluated by a panel of experts 
13
made up of two patients with CIPN and two physicians with knowledge of CIPN 
symptoms.  No other validity or reliability testing was reported (Ostchega et al., 1988). 
________________________________________________________________________
During the last three days:
1. Did you have any difficulty buttoning buttons?
2. Did you have any stiffness or tightness in your hands or feet?
3. Did you feel clumsy?
4. Did you feel pain in your hands?
5. Did you feel pain in your feet?
6. When holding an object in your hand, were you able to feel its shape?
7. Did you have tingling in your hands or feet?
8. Did you have numbness in your hands or feet?
________________________________________________________________________
Figure 2. Original Peripheral Neuropathy Scale.
The authors of this instrument conducted a descriptive retrospective study  
involving 30 people with CIPN. Ten were women who had been treated with cisplatin for 
ovarian cancer and 20 were men who had been treated with cisplatin for testicular cancer. 
Five of the women had completed cisplatin therapy less than one year before the 
interviews. The rest of the participants had completed cisplatin therapy from 1-4 years 
prior to the interview. The goals of the study were to: 1) explore the effects of CIPN on 
quality of life 2) determine if symptoms decrease over time, and 3) determine factors that 
predict variability in symptoms. Data were collected by phone interview or personal 
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interview using the EORTC QOLQ, the Satisfaction with Life Scale (SWLS) and the 
PNS. The study demonstrated that more severe CIPN is positively correlated with fatigue 
and malaise (r=.69, p<.001), psychological distress (r=.36, p<.05) and negatively 
correlated with subjective sense of well-being (-.52, p<.001). Participants with severe 
symptoms were less able to perform ADL’s (p=.00) and usual work (p=.05) than those 
with mild symptoms. In addition, time since treatment was associated with less severe 
symptoms (r=-.48, p<.05) (Ostchega et al., 1988). 
The PNS was the first scale designed to measure CIPN but it had many problems 
that limited its usefulness in further research. Items were worded in the past tense, 
possibly causing confusion to participants who are actively experiencing symptoms.  
Reliability and validity were not thoroughly evaluated by the authors. In addition, the 
PNS evaluates character of neuropathic symptoms, but motor symptoms like muscle 
weakness and muscle pain were not included, presumably because these are not common 
neurologic toxicities of cisplatin. The three items evaluating physical function; difficulty 
buttoning, difficulty feeling the shape of an object in the hand, and clumsiness failed to 
capture the wide range of physical limitations that CIPN can produce. 
Sixteen years later, Almadrones and colleagues (2004) revised the PNS and 
evaluated psychometric properties in 88 women receiving chemotherapy for ovarian 
cancer.  This time the PNS was combined with items from the Gynecologic Oncology 
Group Performance Status Scale (Figure 3) to more thoroughly evaluate aspects of 
physical function related to CIPN. The same four point system for rating presence of 
symptoms used by Ostchega, Donohue and Fox (1988) was retained. The original PNS 
15
was expanded to 11 items by separating hand symptoms from foot symptoms and items 
worded using  past tense were reworded to reflect present tense. The resulting PNS 
contained 11 items and scores ranged from11 to 44 with higher scores corresponding 
with more severe neuropathic symptoms. Scores on the GOG Performance Status Scale 
ranged from 8-40 with higher scores indicating more physical limitations (Almadrones, 
McGuire, Walczak, Florio, & Tian, 2004). 
____________________________________________________________________
Physical Function
1. Do you need help with eating, dressing, washing, or using the toilet?
2. Do you have to stay indoors most or all of the day?
3. Are you in bed or a chair most of the day?
4. Do you have trouble either walking a short distance or climbing one flight of 
stairs?
5. Do you have trouble bending, lifting, or stooping?
6. Do you have trouble either taking a walk or climbing a few flights of stairs? 
Role Function
7. Does your condition keep you from working at a job or doing household jobs?
8. Are you limited in any way doing your work or household jobs?
__________________________________________________________________
Figure 3. GOG Performance Status Scale.
Participants in this study were part of a phase III clinical trial comparing the 
efficacy and tolerability of six cycles of cisplatin and cyclophosphamide to six cycles of 
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cisplatin and paclitaxel. Questionnaires were administered to patients before 
chemotherapy was initiated (T1) and again at the end of six cycles of chemotherapy (T2). 
Sixty-seven patients completed the questionnaires at the end of the study. Internal 
consistency reliability was evaluated using Cronbach’s alpha. Cronbach’s alpha 
coefficients before chemotherapy and after six cycles of chemotherapy demonstrated 
internal consistency for the peripheral neuropathy scale (alpha = .91-.92), physical 
function (alpha =.89-.91), and role function scales (alpha = .92-.96). Two items in the 
peripheral neuropathy scale, difficulty buttoning (r = .66 at T1 and r= .36 at T2) and 
difficulty feeling objects in the hand (r=.26 at T1 and r= .31 at T2) were not highly 
correlated with total scores. Construct validity was assessed at T2 by correlating scores 
on the GOG toxicity criteria for peripheral neuropathy to scores on the PNS using 
Spearman’s rank correlation test of association. Results support the PNS as a valid 
measure of peripheral neuropathy.  Exploratory factor analysis was used to evaluate 
construct validity. Results suggest that the peripheral neuropathy scale is comprised of 
hand neuropathy and foot neuropathy subscales (Almadrones et al., 2004). 
The revised PNS is better designed and has undergone one study evaluating its 
psychometric properties but still does not thoroughly evaluate neuropathic symptoms.  
No items evaluating motor symptoms were added. The PNP/GOG Performance Status 
Scale still does not assess physical function specifically enough to provide meaningful 
information. It includes general measures of physical function that are likely to be 
affected by cancer symptoms or treatment related fatigue. It does not assess the areas of 
daily functioning that are most likely to be affected by CIPN like driving, picking up 
17
objects, or writing.  In addition, it does not assess symptom severity, symptom distress, or 
timing of symptoms. 
FACT/GOG Neurotoxicity Subscale
The FACT/GOG neurotoxicity scale (FACT/GOG-Ntx) was developed in 1998 
through a collaboration between the Gynecologic Oncology Group (GOG) and the 
authors of the Functional Assessment of Chronic Illness Therapy (FACT) (Calhoun et al., 
2003) (Appendix A). The FACT/GOG-Ntx evaluates health related quality of life in 
cancer patients with CIPN. A four point rating system with possible responses include 0 
= not at all, 1 = a little bit, 2= somewhat, 3 = quite a bit, and 4 = very much is used 
(Calhoun, et al., 2003).
Initial psychometric evaluation of the FACT/GOG-Ntx involved data from two 
studies of women with ovarian cancer. One group of 60 women receiving paclitaxel and 
carboplatin completed the FACT/GOG-Ntx and also received a complete neurologic 
exam. Neurologic examination was completed before the first cycle of chemotherapy and 
this group served as a reference group. All participants in the second group of 43 patients 
had grade two or higher peripheral neuropathy, numbness in hands/feet, hearing loss or 
blurred vision. They also completed the FACT/GOG-Ntx.  Both groups were reassessed 
at 3 month intervals until 12 months following completion of chemotherapy. Scores 
between the two groups were then compared in order to evaluate discriminate validity. 
Responsiveness, or sensitivity to change, was evaluated by comparing changes over time 
between the two groups. Construct validity was evaluated by examining correlations 
between FACT/GOG-Ntx scores and neurologic exam data (Calhoun, et al., 2003).  
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Cronbach’s alpha coefficients for the neurotoxicity subscale exceeded the 
predetermined level of  .70 in 11 out of 12 assessments demonstrating internal 
consistency reliability. Mean scores between the two groups on the neurotoxicity 
subscale differed significantly at baseline, 3 month follow-up and 6 month follow-up, 
demonstrating responsiveness over time. Correlations between FACT/GOG-Ntx scores 
and some elements of neurologic exam data were significant, while others were not. 
Other studies have also shown that patient report does not correlate well with neurologic 
exam (Calhoun et al., 2003). 
  The FACT/GOG-Ntx was modified for use in patients receiving oxaliplatin by 
Kopec and colleagues (2006). Two additional items pertaining to sensitivity to cold were 
added and the resulting scale was administered to 395 patients with colon cancer. 
Participants received either a non-neurotoxic chemotherapy regimen with  leucovorin and 
5-fluorouracil (n=206) or a neurotoxic regimen including leucovorin, 5-fluorouracil and 
oxaliplatin (n=189). Neurotoxicities were also assessed using The National Cancer 
Institute’s (NCI) common toxicity criteria for peripheral neuropathy. This is a clinician 
rated assessment with scores as follows: 0=normal, 1=loss of tendon reflexes or 
paresthesia (including tingling) interfering with function but not activities of daily living, 
3= sensory loss or paresthesia interfering with activities of daily living or 4= permanent 
sensory loss that interferes with function. Questionnaires were completed at baseline, 3 
months after initiation of chemotherapy, and at 6, 12, and 18 months following initiation 
of chemotherapy (Kopec et al., 2006).
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Cronbach’s alpha for the new scale at the 6 month measurement was 0.85.  Factor 
analysis yielded a single factor solution, indicating that the scale is uni-dimensional. 
Correlations between items and between each item and the total score were calculated. 
Relationships between each item and the NCI common toxicity criteria were calculated. 
Trouble hearing, ringing or buzzing in the ears and difficulty breathing when exposed to 
cold, and feeling weak all over had correlations less than 0.2 with the NCI common 
toxicity criteria.  Trouble hearing, ringing or buzzing in the ears and difficulty breathing 
when exposed to cold had item-total correlations less than 0.4. Difficulty breathing when 
exposed to cold was removed from the scale based on those results. Sensitivity to change 
was assessed by the effect size (mean scores/standard deviation) for changes from 
baseline to the 3 month assessment. An effect size greater than 0.8 signifies a large effect. 
The effect size for changes in scores was .83 for the original scale and 1.10 for the final 
scale (Kopec et al., 2006). 
A third study evaluating the psychometric properties of the FACT/GOG-Ntx was 
conducted  with 116 chemotherapy-naive women being treated with cisplatin, 
doxorubicin, and paclitaxel for endometrial cancer (Huang et al., 2007). Participants 
completed the FACT/GOG-Ntx prior to administration of each chemotherapy cycle for 
up to seven cycles. The National Cancer Institute’s (NCI) Common Toxicity Criteria for 
peripheral neuropathy was also calculated by a clinician before each chemotherapy cycle. 
Principal component analysis was used to determine the number of latent constructs. The 
authors concluded that the 11 item neurotoxicity subscale assesses four latent constructs: 
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sensory neuropathy, motor neuropathy, hearing neuropathy, and neuropathy related 
dysfunction (Huang et al., 2007).
 Internal consistency reliability was assessed using Cronbach’s alpha. Values 
ranged from 0.80 to 0.85 for the total scale and between 0.7 and .91 for an abbreviated 
four item version of the scale. Construct validity was assessed by examining item-total 
correlations. All correlations were weak to moderate (r=0.3-0.4) at baseline. Correlations 
between the sensory neuropathy items and the total score got progressively stronger, 
reaching 0.6-0.8 by the end of the study. Other item-total correlations either remained the 
same or were slightly increased by the end of the study. Significant differences between  
a second group of patients ( n=129) receiving a less neurotoxic chemotherapy regimen 
(cisplatin and doxorubicin only) were also used as evidence of construct validity. 
Differences between mean scores from baseline (3.67) to before the seventh cycle (8.13) 
were significant, demonstrating responsiveness of the subscale to changes over time 
(Huang et al., 2007).  
Four items accounted for 80% of the variance and 63% of changes in the subscale 
over time. These items made up the sensory subscale and were as follows: 1) numbness 
or tingling in the hands 2) numbness or tingling in the feet 3) discomfort in the hands 4) 
discomfort in the feet. The authors concluded that when patient burden is a concern, the 
abbreviated four item version may be used. The abbreviated four item scale allows for 
quick assessment but may not be responsive to changes over time or provide enough 
information to accurately capture the entire symptom experience (Huang et al., 2007).  
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Cella and colleagues (2003) added five items for assessment of taxane related side 
effects to the FACT/GOG-Ntx subscale. They evaluated the psychometric properties of 
the new scale on 240 patients receiving paclitaxel and carboplatin for treatment of non-
small cell lung cancer (Cella, Peterman, Hudgens, Webster, & Socinski, 2003). The 
resulting taxane specific scale is referred to as the FACT-taxane. Additional items 
pertained to feeling bloated, having edema of the upper or lower extremities, having pain 
in the fingertips or feeling bothered by the appearance of hands or nails.
 Questionnaires were administered at baseline and at 6, 12, and 26 weeks and 
included the FACT-taxane and the Functional Assessment of Cancer Therapy-General 
(FACT-G), a general measure of health related quality of life for people with cancer. 
Internal consistency reliability of the FACT/GOG-Ntx was demonstrated again, with 
Cronbach’s alpha coefficients ranging from .82 to .86 for the FACT/GOG-Ntx and .84-
.88 for the taxane specific items. Responsiveness to change over time was supported by 
the findings of significant worsening of neurotoxic symptoms from baseline to the six 
week assessment (p=0.000) as well as from the six week to the twelve week assessment 
(p=0.000) (Cella et al., 2003). 
The FACT/GOG neurotoxicity subscale is without a doubt the most widely used 
and thoroughly evaluated instrument available for CIPN. Unfortunately, multiple changes 
to the scale have been required based on the population being studied and which 
neurotoxic agents were administered. There is a need for an instrument that can be used 
across populations receiving different neurotoxic chemotherapies without a need to 
change the contents of the scale. Some of the items evaluating physical function 
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including trouble buttoning buttons and feeling the shapes of objects in the hands have 
had low item-total correlations in prior studies. The hearing neuropathy items have also 
shown low item-total correlations in previous studies. The neuropathy related dysfunction 
subscale fails to evaluate common aspects of physical performance affected by CIPN and 
the instrument does not evaluate timing of symptoms, or symptom distress. 
Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20
The Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 
20 (QLQ-CIPN20) is another neuropathy scale designed to supplement one of the 
EORTC Quality of Life questionnaires (Postma et al., 2005). It was developed based on 
results of a literature search, a panel of experts, and interviews with 68 patients with a 
variety of malignancies receiving neurotoxic chemotherapy. The most prevalent 
symptoms reported by patients included numbness and tingling, problems with standing 
or walking, difficulty opening a bottle or jar, difficulty getting out of a chair, and leg 
weakness. The resulting QLQ-CIPN20 contains three scales evaluating sensory, motor, 
and autonomic symptoms and functioning. It was pre-tested on 44 participants in Europe 
and demonstrated adequate internal consistency reliability for the sensory scale 
(Cronbach’s alpha 0.82), the motor scale (Cronbach’s alpha 0.73), and the autonomic 
scale (Cronbach’s alpha 0.76). The participants had all received taxanes, platinum-based 
drugs, or vinca-alkaloids (Postma et al., 2005). More extensive psychometric evaluation 
is in progress but no other studies of the QLQ-CIPN20 were found in a recent search of  
PubMed. This scale needs further evaluation of psychometric properties before it can be 
considered a valid tool for measuring CIPN.
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Summary
In summary, a review of the literature resulted in identification of three self-report 
instruments for chemotherapy induced peripheral neuropathy. The instrument that was 
identified most frequently was the FACT/GOG-Ntx. It has been the subject of at least 
four studies which support its use as a reliable and valid instrument. Reliability and 
validity of the PNS and QLQ-CIPN20 also have been evaluated but studies to date have 
involved small samples. None of the instruments thoroughly evaluate key aspects of 
CIPN, particularly timing of symptoms, severity of symptoms or interference with 
physical functioning. 
These studies support the inclusion of numbness, tingling, pain or discomfort, 
arthralgias/myalgias, loss of balance, muscle weakness, generalized weakness, cold 
sensitivity, and interference with usual activities in assessment of CIPN and confirm the 
need for development of new, more comprehensive self- report tools for CIPN. Such an 
instrument should be applicable to patients receiving any type of neurotoxic 
chemotherapy, should specifically assess timing of symptoms, address the individual 
level of distress that each symptom causes for the patient, and should thoroughly evaluate 
neuropathic impairment with physical function.
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Chapter Three
Phase I Method, Results and Discussion
The first phase of instrument development was to learn, from patients who were 
currently experiencing CIPN, how they describe symptoms, how symptoms affect their 
daily lives, and what they found most bothersome about the experience of CIPN. A 
qualitative study of patients with chemotherapy induced peripheral neuropathy was 
conducted between August of 2007 and February of 2008. The methods and outcomes of 
this study are presented in this chapter. 
Method
Sample and Setting. The researcher conducted semi-structured interviews with 15 
participants who had neuropathic symptoms and who had been treated with taxanes, 
platinum-based drugs, vinca alkaloids, or thalidomide within the previous three years. 
Approval for the study was obtained from the Institutional Review Board (IRB) of the 
University of South Florida. Informed consent was obtained.  Participants were recruited 
from an outpatient medical oncology clinic in Central Florida, where the author of this 
manuscript works as a nurse practitioner and spent 12 years as a chemotherapy nurse. 
Many of the participants were previously known to the investigator.
Procedures. Semi-structured interviews were conducted with the participants 
while they were at the clinic, were recorded, and professionally transcribed. Patients were 
asked the following questions:
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1. Tell me about any of the following symptoms that you have experienced since 
starting chemotherapy: numbness, tingling, sharp, stabbing or throbbing pain, a 
“pins and needles” sensation or feeling like part of your body is “asleep”.
2. What other words would you use to describe these symptoms?
3. How have these symptoms affected your daily life?
4. What things have these symptoms interfered with your ability to do?
5. What do you find most troubling about these symptoms?
6. Is there anything else you would like to share with me about these symptoms?
Relevant comments made by participants during the course of the interview were 
recorded. Demographic information was obtained from the medical record including age, 
gender, cancer type, name and cumulative dose of neurotoxic chemotherapy drug used 
and whether chemotherapy doses were altered or chemotherapy was interrupted as a 
result of peripheral neuropathy. 
Transcripts were reviewed numerous times for relevant content. Each transcript was 
examined for neuropathic symptoms and descriptors. Each descriptor was entered as a 
variable into a database and coded as a one if the patient reported it or a zero if they did 
not report it. Terms that described similar concepts were combined. For instance, patients 
used a variety of terminology to describe loss of balance including “clumsiness”, “loss of 
balance”, “dizzy in the head” and “not being able to walk”. These were categorized 
together as “loss of balance”. Data were analyzed using the Statistical Software Package 
for the Social Sciences (SPSS) version 16.0 and confirmed using Atlas TI. Descriptive 
statistics including frequencies and percentages were analyzed. Items for instrument 
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development were selected from the quantitative analysis reported below. The 
preliminary version of the CIPNAT was developed based upon the results of this study 
and is supported by existing literature on neuropathic symptoms.
Results
Demographics. The sample was almost equally divided between men and women 
with 8 males and 7 females ranging in age from 42 to 84. Participants were primarily 
Caucasian and had lung cancer, breast cancer, colon cancer, multiple myeloma or 
cholangiocarcinoma. The majority were treated with taxanes or oxaliplatin (Table 1). 
Over fifty-three percent had not yet had a dose reduction or discontinuation of treatment 
while 46.6% had dose reductions or discontinuation of the neurotoxic agent at the time of 
the interview. 
Table 1. Frequencies and percentages for race, gender, cancer type and neurotoxic agent.
Variable N Percentage
Race
   White/Caucasian
   African-American
14
1
93
7
Gender
   Male
   Female
8
7
53
47
Cancer Type
   Lung
   Breast
   Colorectal
   Multiple Myeloma
   Cholangeocarcinoma
4
4
4
2
1
27
27
27
13
7
Neurotoxic agent
   paclitaxel
   docetaxel
   vinorelbine
   oxaliplatin
   thalidomide
4
3
1
5
2
27
20
7
33
13
27
Borderline case. One borderline case described symptoms that were dissimilar to 
the other patients. Her symptoms were also inconsistent with the literature on 
chemotherapy induced neuropathy.  She had mild, temporary neurological symptoms 
following her first treatment with oxaliplatin. These symptoms subsided within days after 
the first treatment. Her second treatment resulted in immediate acute onset of shortness of 
breath and anxiety probably attributable to oxaliplatin induced laryngopharyngeal spasm.
Non-painful symptoms. Patients reported a variety of non-painful symptoms 
including numbness, short term memory loss, trouble concentrating, loss of balance, 
muscle weakness, clumsiness, loss of depth perception, lack of coordination, dizziness 
and generalized weakness (Table 2). Of these symptoms, numbness, muscle weakness, 
loss of balance, and generalized weakness were reported by at least 33% of participants. 
All of the patients except the borderline case reported numbness of the fingers and/or 
toes. Patients frequently described simultaneous pain or discomfort and numbness. 
Table 2. Frequencies and percentages for non-painful symptoms.
Variable N Percentage
Numbness 14 93
Muscle weakness 8 53
Loss of balance 8 53
Generalized weakness 6 40
Short-term memory loss 2 13
Trouble concentrating 2 13
Lack of coordination 2 13
Loss of depth perception 1 7
Risk of injury. Near or actual injuries were reported by almost 50% of patients, 
and were reported to result primarily from non-painful symptoms. A patient with breast 
cancer reported having to go to the emergency room because of loss of balance and
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falling twice at home, “I hit my right arm and cut the heck out of it on the foot of the bed; 
I haven’t figured out how yet… my arm so bad …but then the second time, I fell forward 
and hit my chest of drawers and it blackened my eye, my cheek and my nose, well, in 
fact, it cracked my nose.”Another said “I looked down at my toes one day and I had a 
purple toe and I didn’t know how I had a purple toe; I didn’t remember dropping 
(anything on it), obviously I dropped something pretty hard and I literally had a purple 
toe for it’s going on three months now and you don’t feel it; I mean, I don’t feel the 
pain.” 
A patient in her forties reported, “I always take baths and slowly, I noticed I was 
having a hard time getting myself to stand up to get out of the bathtub. I cannot get out of 
the bathtub by myself.  Sometimes I do it, but I know one of these days I’m going to end 
up probably knocking my teeth out or knocking my face off or something because I’m 
trying to push on the side of the tub to push up and it’s slippery.” Forty percent of 
patients who were completely ambulatory before starting chemotherapy required assistive 
devices such as a cane or walker because of neuropathic symptoms. One patient with 
lung cancer reported, “I don’t have any feeling so I lose my balance, but I get a lot of 
weakness in my legs and my thighs. Sometimes when I’m on the cane, sometimes I’ll 
lose my balance and… like my leg will give way, just for a short period.”
Painful symptoms. The most commonly reported painful symptoms were tingling, 
burning, muscle aches, and sensitivity to cold (Table 3). These symptoms were reported 
in at least 33% of patients. Although two-thirds of participants (n=10) used the word 
“pain” to describe their experience, one-third of participants did not use the word “pain” 
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(n=5). Patients described a host of unpleasant sensations including feelings that their feet 
were “ice cold”, they were “walking on hot coals”, “walking on a rock on the bottom of 
your feet” or with “sandpaper on the bottom of your feet”.  They often had trouble 
describing these symptoms succinctly and struggled to put words to their experience. One 
female patient described her experience in the following way: “Yeah, it feels like…I 
think I’ve got something crawling on me; I reach down and there’s nothing”. One female 
under treatment with docetaxel for breast cancer responded to a question about how 
neuropathic symptoms had affected her life with the following: “With my husband and I, 
intimately, you know, as far as my sex life I’m hurting, I just…I hurt and my legs really 
hurt and it’s been very dragging on my quality of life very much.”
Patients who did have pain described it using a variety of terms. Although burning 
was the adjective most often used to describe pain, several other descriptors including 
sharp, shooting, pins and needles, muscle aches, soreness, trampling, stabbing, electric-
like and pressure were used. The location of pain was generally the upper and/or lower 
extremities, but two participants described jaw pain and two participants described joint 
pain. Both of the patients who described jaw pain had received oxaliplatin. Both of the 
patients who described joint pain had received taxanes. Patients occasionally reported 
muscle tremors. Sensitivity to cold temperatures was not limited to patients receiving 
oxaliplatin but also occurred in patients receiving other neurotoxic chemotherapies. No 
specific pattern in timing of painful symptoms was identified.
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Table 3. Frequencies and percentages for painful symptoms.
Variable N Percentage
Tingling 7 47
Cold Sensitivity 7 47
Pain 10 67
     Burning 6 40
     Muscle aches 5 33
     Pins and needles 4 27
     Soreness 3 20
     Tremors 3 20
     Jaw Pain 2 13
     Joint pain 2 13
     Sharp pain 2 13
     Shooting pain 2 13
     Trampling pain 1 7
     Stabbing pain 1 7
     Electric like pain 1 7
     Pressure 1 7
Interference with Activities. Patients described a variety of ways in which 
neuropathic symptoms interfered with manual dexterity, general activities, activities of 
daily living, driving, writing, picking up things, work, sleep, walking, hobbies, household 
duties, and exercise (Table 4). One patient, a physician who finished chemotherapy over 
two years ago, described how neuropathies have interfered with his ability to perform his 
job.  “Both the combination neuropathy and the sciatic nerve problem forced me to close 
my medical practice. When I finished with the chemo, the neuropathy really prevented 
me from doing the endoscopic procedures that I had done previously or standing for long 
periods of time. In my specialty of gastroenterology, you have to stand for hours at a 
time. I had to close the office.  So for me, that’s been a major personal effect. It’s 
changed my whole life.” Unfortunately, he also reported his neuropathic symptoms had 
worsened, rather than regressed, since he completed his chemotherapy. 
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Many described how neuropathic symptoms interfere with their usual activity. 
One female who had received thalidomide for multiple myeloma spoke of it in this way: 
“I just get discouraged and down and…cause I was always a doer, person that was on the 
go doing things and I can’t…can’t do any of that.” Another patient, an attorney who also 
is disabled as a result of advanced lung cancer reported, “I didn’t realize how much I 
used my hands.  My writing is shot; it was never very good to begin with and even 
typing, I’ve even quit fooling around with e-mail because it’s just too painful. I’m not 
driving very much anymore; driving feels weird too. I can barely feel the pedals.”  
Another male patient who previously enjoyed restoring antique automobiles was 
distraught over the fact that he no longer has the manual dexterity to work on his cars. 
When asked about how neuropathic symptoms have interfered with his ability to 
participate in this activity he reports “I can wax them; that’s about it, as far as working on 
them, no. I get my son to do that. It’s because my fingers are numb and I mean, if I go to 
pick up a screwdriver; I don’t know it’s there; I have to watch and make sure I have it; it 
ain’t like you can feel it when you pick it up. And when I walk, it just feels like I’m 
dragging dead feet with me and if my shoe comes off, I don’t know it until it’s off,  so I 
can’t do things.  I have to depend on my son if I need to change an alternator or 
something; I have to get him to do it but I want to do it cause I want to get my hands 
greasy. I want to pull a motor out or something, put another motor in, I can’t do it.  I hate
to ask people for help. I have been around trucks and cars all my life.  So now the brakes 
are put on.”
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Instrument Development
The preliminary version of the CIPNAT (Appendix B) was developed based upon 
the above findings. The overall design of the instrument, as previously mentioned,  is 
based upon the theoretical perspective that evaluation of symptoms should include 
character, timing, intensity and distress (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; 
Lenz, Suppe, Gift, Pugh, & Milligan, 1995). Character is evaluated initially by asking 
participants whether they are experiencing a specific neuropathic symptom. Choices are 
limited to “yes” or “no”. If they respond “yes” they are directed to answer additional 
items evaluating timing, intensity, and distress. If they answer “no”, they skip items 
pertaining to that symptom and move to the next symptom. This approach was taken to 
minimize burden to patients by not having them respond to questions that are not 
applicable to their individual symptoms. 
The symptom interference items ask patients to measure on a numeric rating 
scale, how neuropathic symptoms are interfering with their ability to carry out usual 
activities. Participants will only complete symptom interference items if they reported the 
presence of at least one neuropathic symptom. Specific items selected for inclusion are 
discussed in the following sections.
Because participants in this study reported numerous injuries or potential injuries 
as a result of neuropathic symptoms, the author chose to include assessment of injury 
related to symptoms as part of the instrument. Participants are asked if they have had any 
injuries as a result of neuropathic symptoms. Possible responses to this item are either 
“yes” or “no”.
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Painful symptoms. Among painful symptoms, burning pain, tingling, cold 
sensitivity, and muscle aches were the most frequently reported. These four most 
prevalent symptoms occurred in at least 33% of participants and therefore were included 
as items on the preliminary version of the CIPNAT. Because there was a great degree of 
heterogeneity in descriptions of pain, instead of asking about “burning” pain specifically, 
a more general item asking whether patients have developed pain since starting chemo 
and allowing them to select from a list of reported pain descriptors including burning, 
sharp, shooting, electric-like, stabbing, pins and needles, sore, or other was more 
appropriate. Next to the word other, a line for patients to include their own description 
was included. This allows for a more thorough assessment of painful neuropathic 
symptoms. Tingling in the hands is evaluated separately from tingling in the feet. 
Previously developed  instruments for CIPN have also evaluated tingling in the feet and 
tingling in the hands separately (Almadrones et al., 2004; Huang et al., 2007) and factor 
analysis in earlier studies suggests that CIPN may be comprised of  two factors; hand 
symptoms and foot symptoms (Almadrones et al., 2004). In addition, tingling and 
numbness are believed to begin in the most distal parts of  the extremities (fingertips and 
toes) and progressively involve more of the extremities. Involvement of  more of the 
extremities correlates with more severe CIPN (Ocean & Vahdat, 2004; Visovsky, 2003; 
Wilkes, 2007). Accordingly, evaluation of tingling and numbness by the CIPNAT 
includes assessment of how much of the upper and lower extremities are involved. 
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Non-painful symptoms. Among non-painful symptoms, numbness, muscle 
weakness, loss of balance, and generalized weakness were reported by at least 33% of 
patients and were included as items for the CIPNAT.  Separate items assess foot and hand 
numbness, again based upon the results of prior studies (Almadrones et al., 2004). 
Symptom interference. Participants in this study reported interference with 13
aspects of daily life including a general category for activities of daily living (Table 4). 
Most of the categories of interference involved physical outcomes and were included as 
items on the CIPNAT. Because the purpose of the CIPNAT is to evaluate specific 
physical symptoms of CIPN, general activity, hobbies and relationships were not initially
included. These were thought to represent psychosocial concepts that do not fit well with 
the other items. The resulting 10 item symptom interference scale asks participants to 
evaluate how much neuropathic symptoms as a whole interfere with their ability to: walk, 
pick up things, drive, do household chores, work, use their fingers/hands to do things 
(manual dexterity), write, exercise, sleep, and engage in sexual activity. If patients do not 
normally engage in the selected activity, the instructions direct them to mark zero (not at 
all). 
Table 4. Frequencies and percentages for interference with usual activities
Interference with N Percentage
Activities of daily living 8 53
Walking 7 47
Picking up things 6 40
Driving 5 33
Hobbies 5 33
Relationships 4 27
Household chores 3 20
Work 3 20
Manual Dexterity 3 20
Writing 2 13
Exercise 1 7
Sleep 1 7
Sexual activity 1 7
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Discussion
This phase I study highlights which neuropathic symptoms are reported most 
frequently in cancer patients receiving chemotherapy, how patients describe their 
symptoms, and how these symptoms affect their daily lives. Patients are viewed as 
experts on their own experience with CIPN.  The resulting CIPNAT was developed from 
the responses of participants. This study provides critical information about which 
neuropathic symptoms are frequently reported by patients as well as what terminology 
they use to describe these symptoms and how symptoms affect their daily lives. 
In spite of the usefulness of this study, several limitations exist. The sample size 
was small, limiting the generalizability of the results. The sample was selected from a 
single geographic location from a site location where patients tend to be of above average 
education and socioeconomic status, although no data on these variables were collected. 
Few minorities participated in this study. Results may differ based on racial or ethnic 
variations. Perhaps the most significant limitation is the possibility of bias in the study. 
The dual role of the researcher of health care professional and researcher may have 
caused patients to withhold information that may influence healthcare decisions. It is also 
possible that the pre-established rapport between participants and researcher allowed for 
more honest and straightforward discussion. The selection of participants was not random 
but purposive and therefore the experience of these patients may differ from those in a 
randomly drawn sample. 
Several of the patients had completed chemotherapy up to three years ago and still 
were experiencing neuropathic symptoms. Because of the significant lapse in time from 
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onset of symptoms, their descriptions may not be entirely reflective of their actual 
experience. In addition, no comprehensive assessment of neuropathic symptoms was 
conducted. Patients were free to report any neuropathic symptoms they chose to discuss 
in any amount of detail they were comfortable with.  They may have experienced 
additional neuropathic symptoms that were not discussed in the interview. Conversely, 
patients may have reported symptoms during the interview that do not have an underlying 
neuropathic etiology. Ability to differentiate cause of symptoms varies from person to 
person. The opportunity to speak of their symptom experience in an open ended 
discussion may have caused some individuals to report symptoms that were distressing 
but not necessarily of neuropathic origin. To compensate for this limitation, the selection 
of items for the CIPNAT was limited to symptoms that had been previously documented 
in earlier research as having an underlying neuropathic cause. 
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Chapter Four
Phase II Method, Results and Discussion
This chapter discusses the second phase of instrument development and testing, 
review by a panel of experts. Review by a panel of experts is helpful in evaluating
content validity and implementing any necessary changes to the instrument (Waltz, 
Strickland & Lenz, 2005). This chapter discusses methods and results of this Phase II 
study. Scoring of the CIPNAT also is discussed.
Method
The second phase of instrument development was to evaluate content validity of 
the first draft of the CIPNAT. This was accomplished by consultation with a panel of five 
experts. Experts evaluated whether items developed from the results of the phase I study 
accurately represent the characteristics of CIPN.
Consultants.A neurologist, a medical oncologist, two PhD prepared registered 
nurses and an oncology certified registered nurse made up the panel of experts. Members 
of the panel of experts were selected based on their knowledge and experience with 
CIPN. Requirements for selection in the panel of experts were direct and consistent 
involvement in the care of persons with CIPN or publication on this topic. 
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The consultants are described here. Ron D. Schiff, MD, PhD is a board certified 
medical oncologist in Tampa. He has extensive knowledge of chemotherapy and its 
related side effects. Before entering private practice, he was a professor at the University 
of South Carolina School of Medicine. He completed his residency in oncology at 
Memorial Sloan Kettering Cancer Center in New York.
Leon Prockop, MD is a board certified neurologist in Tampa, Florida. He is a 
professor at the University of South Florida College of Medicine. He is a graduate of 
Princeton University and the University of Pennsylvania, College of Medicine. He has 
authored at least 73 peer reviewed journal articles and 61 book chapters on a variety of 
subjects within his specialty. 
Constance Visovsky, PhD, ARNP  is a nurse practitioner and associate professor 
at the University of Nebraska. She has published at least five articles since 2003 on 
CIPN. She served on an Oncology Nursing Society taskforce that evaluated the  literature 
pertaining to CIPN and made recommendations for nursing management (ONS, 2005).
Marie Bakitas, DNSc, ARNP, FAAN is an assistant professor at Dartmouth 
Medical School and Nurse Practitioner at Dartmouth-Hitchcock  Medical Center in 
Hanover, New Hampshire. She is also a postdoctoral fellow at the Yale University 
Medical Center in New Haven, Connecticut. She published a qualitative study on CIPN 
entitled “Background noise: the experience of chemotherapy-induced peripheral 
neuropathy” (Bakitas, 2007). 
Patricia Friedel, RN, BSN, OCN is a registered nurse in the infusion center at 
Moffitt Cancer Center. She received her bachelor’s degree from Kent State University in 
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1989. She has been a chemotherapy nurse in the Moffitt Infusion Center for five years 
and is currently working toward her Master’s degree at the University of Tampa. 
Procedures. An evaluation tool was designed to help the consultants provide 
feedback on the CIPNAT.  The Content Validity Assessment tool provided consultants 
with operational definitions necessary to evaluate the items as well as a list of items from 
the CIPNAT. Each expert was provided with the Content Validity Assessment tool and 
asked to rate individual items for relevance to either CIPN as a whole or to specific 
neuropathic symptoms. The rating system was as follows: 1 = the item is not relevant to 
CIPN or to a specific neuropathic symptom, 2 = the item is somewhat relevant to CIPN 
or to a specific neuropathic symptom, 3 = the item is quite relevant to CIPN or to a 
specific neuropathic symptom or 4 = the item is very relevant to CIPN or to a specific 
neuropathic symptom (Grant & Davis, 1997). The experts were also asked to evaluate 
how comprehensive the CIPNAT is in its approach to evaluating symptoms, how 
appropriate the items are for patients in terms of  how easy it is to understand each item,
and whether items are written at an appropriate grade level. There were also areas for 
consultants to write in additional comments.
Data obtained from the panel of experts was analyzed by calculating a content 
validity index (CVI) on every item and on the entire instrument. The CVI is defined as 
the proportion of items given a rating of quite relevant or very relevant by the experts. 
Items with a CVI of .80 were evaluated for deletion or revision. This was a conservative 
approach because a CVI of 0.8 is considered acceptable in most cases (Wynd, Schmidt, 
& Schaefer, 2003). The CVI for the entire instrument was calculated as a mean CVI for 
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all items. Comments and suggestions by the experts were taken into account and 
appropriate items were added or deleted from the instrument as needed.  
Results
CVI’s for individual items ranged from 0.8-1.0. Twenty-two of 85 items had 
CVI’s of .80 and 63 items had CVI’s of 1.0. The CVI for the entire instrument was 0.95. 
Items related to muscle or joint aches and pain were revised. Items related to generalized 
weakness were eliminated and items related to muscle weakness were revised. Additional 
items related to interference with “relationships”, “hobbies or leisure activities”, and 
“enjoyment of life” were added.  Items pertaining to frequency of symptoms were 
revised. Minor changes in wording were made to several additional items for the purpose 
of clarity. Items containing terms that were thought to be “too medical” were also 
revised. Items that were redundant or not critical to the evaluation of CIPN were 
eliminated based on feedback from experts that the instrument was too lengthy.  The 
resulting version of the CIPNAT contains a total of 69 items evaluating nine specific 
neuropathic symptoms, neuropathic interference with usual activities, and injuries 
resulting from neuropathic symptoms.  The instructions for patients were revised to 
encourage the patient to allow them to ask someone to read the questions to them and 
record their responses. Instructions also encouraged rest during completion as necessary.
Scoring
The original version of the CIPNAT consisted of 85 items. Revisions to the 
instrument following recommendations by the panel of experts and analysis of the 
content validity index resulted in a 69 item instrument. Forty-five items assess symptom 
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occurrence, severity, intensity and frequency. Fourteen of the 69 items are descriptive 
data which is useful for understanding the entire neuropathic symptom experience but do 
not contribute to the total score. These items make up the symptom experience scale. 
Scores for each scored item range from 0-10. Total symptom experience scores range 
from 0-400 (Table 5). If items are skipped because they are not applicable, a zero score 
on that item is assigned.  Scores on each of the 15 items evaluating symptom interference 
range 0-10. Total interference scale scores range from 0-150. Scores on the symptom 
experience scale are added to the interference score to form a total score.
Discussion
Evaluation of the CIPNAT by a panel of five experts demonstrated content 
validity of the instrument. Changes were made to the CIPNAT based on the 
recommendations of the panel of experts. The suggestions made by the experts resulted in 
a briefer yet more comprehensive instrument.  In future studies, the researcher plans to 
develop an electronic version of the CIPNAT.  An electronic format may be more 
applicable to this type of instrument which is designed to be tailored to each patient’s 
specific symptoms. In scoring this instrument, the author chose to sum scores related to 
symptom prevalence, intensity, severity, and distress. There is some question as to 
whether these scores can be added together to form a symptom experience score or 
whether subscores should be calculated for each dimension of the symptom experience. 
Data from the CIPNAT will be used to test the Theory of Unpleasant Symptoms. Doing 
so may provide useful information as to whether intensity, frequency, and distress have a 
summative effect or need to be examined separately.
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Table 5. Scoring guide.
Description Possible Points Items Contributing to Total Score
Symptom Experience Scale
1 numbness hands 50 1a (10 points)
1b (10 points) (2.5 x 4)
1c (10 points)
1d (10 points)
1e (10 points)
2 numbness feet 50 2a (10 points)
2b (10 points) (2 x 5)
2c (10 points)
2d (10 points)
2e (10 points)
3 tingling hands 50 3a (10 points)
3b (10 points) (2.5 x 4)
3c (10 points)
3d (10 points)
3e (10 points)
4 tingling feet 50 4a (10 points)
4b (10 points) (2 x 5)
4c (10 points)
4d (10 points)
4e (10 points)
5 cold sensitivity 40 5a (10 points)
5c (10 points)
5d (10 points)
5e (10 points)
6 nerve pain 40 6a (10 points)
6c (10 points)
6d (10 points)
6e (10 points)
7 myalgias/arthralgias 40 7a (10 points)
7c (10 points)
7d (10 points)
7e (10 points)
8 muscle weakness 40 8a (10 points)
8c (10 points)
8d (10 points)
8e (10 points)
9 loss of balance 40 9a (10 points)
9b (10 points)
9c (10 points)
9d (10 points)
Score 0-400
Interference
Scale
Various activities 0-150 10a-10o (10 points each)
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Chapter Five
Phase III Method, Results and Discussion
Phase III methods for assessing reliability and construct validity of the CIPNAT 
are presented in this chapter. Results of this study are then presented, followed by  
discussion. Discussion includes importance to nursing and future use of the CIPNAT.
Method
The phase III study was an exploratory, descriptive study designed to evaluate 
validity and reliability of the revised CIPNAT. This phase of the study was conducted at 
the Moffitt Cancer Center and the private medical oncology practice of Ron D. Schiff,
MD, PhD  and Egberto Zayas, MD. For this phase of the study, approval from both the 
Moffitt Scientific Review Board and the University of South Florida IRB was obtained. 
Permission to conduct the study at their practice was obtained from Dr. Schiff and Dr. 
Zayas. All data were collected between August 2008 and October 2008.
A convenience sample of 167 outpatients currently undergoing chemotherapy for 
cancer participated in this study. Eligibility criteria included: 1) a diagnosis of cancer; 2) 
able to speak and understand English; and 3) between 18 and 90 years of age. One 
hundred-twenty seven patients had received at least one chemotherapy treatment with 
paclitaxel, docetaxel, cisplatin, or oxaliplatin within the last 6 months. A comparison
group of  40 neurotoxic chemotherapy naive patients, who were receiving other types of 
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chemotherapy were recruited. Patients were excluded if they had preexisting diabetic 
neuropathy or if they have known dementia or psychiatric illness. 
Instruments
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group 
Neurotoxicity Scale. The Functional Assessment of Cancer Therapy/Gynecologic 
Oncology Group Neurotoxicity Scale (FACT/GOG-Ntx) (Appendix A) is an 11 item 
Likert-type scale assessing neuropathic symptoms (Appendix A). Participants are asked
to rate the extent to which they agree with given experiences over the past seven days. 
Possible responses range from 0 = not at all to 4 = very much. Higher scores correspond 
with a higher degree of neuropathic symptoms. 
Evidence of validity was provided by Calhoun and colleagues (2003) who found 
significant correlations between the FACT/GOG-Ntx and neurological examination 
evaluating sensory symptoms, pin sensibility, strength, deep tendon reflexes, vibration 
sensibility, and nerve conduction. Significant differences in scores from chemotherapy 
naïve individuals and those with known chemotherapy induced peripheral neuropathy 
demonstrated construct validity. Cronbach’s alphas ranged from .78 - .88. 
Chemotherapy Induced Peripheral Neuropathy Assessment Tool. The 
Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT) (Appendix 
B) is the subject of this study. As discussed, it was developed from interviews with 15 
patients with chemotherapy induced peripheral neuropathy. The instrument assesses the 
multi-dimensional characteristics of CIPN including presence of neuropathic symptoms, 
symptom severity, symptom distress and timing of symptoms (Lenz et al., 1997; Lenz et 
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al., 1995). It also assesses neuropathic symptom interference with normal activities and 
patient perception of progression of neuropathic symptoms. 
The initial items for the instrument were selected based on which symptoms were 
most frequently reported by patients in the phase I study.  Symptoms that were reported 
by at least 33% of patients were included. These symptoms make up the symptom 
experience scale. Nine neuropathic symptoms including; numbness in the hands, 
numbness in the feet, tingling in the hands, tingling in the feet, sensitivity to cold
temperatures, nerve pain, muscle/joint aches, muscle weakness and loss of balance are 
assessed. Higher scores on the symptom experience scale correspond with higher degrees 
of CIPN. The second aspect of the CIPNAT is the interference scale. Items in the 
interference scale were reported by patients in the qualitative study (Table 4). Higher 
scores on this scale correspond with greater neuropathic interference with usual activities. 
Demographic data form. A demographic data form (Appendix C) was developed 
for this study.  It includes age, gender, race/ethnicity, income, education, marital status, 
income, years of formal education, employment status, type of cancer, type of 
chemotherapy, number of cycles of chemotherapy, and cumulative dose of neurotoxic 
agent. Chemotherapy information was completed by the researcher with information 
obtained from the medical record.
Procedures
Approvals from both the Moffitt Cancer Center Scientific Review Committee and 
the practice of Dr. Schiff and Dr. Zayas were obtained. Support for the recruitment of 
participants from the Moffitt Infusion Center was obtained from the Clinical Operations 
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Manager of the Infusion Center. Following these approvals, approval from the University 
of South Florida IRB was obtained. Patients who were appropriate for the study were 
identified by referring to a list of current patients which is kept in the nursing station in 
the infusion center. This list describes what chemotherapy regimen patients are receiving 
that day. Patients who were receiving paclitaxel, docetaxel, oxaliplatin, or cisplatin  were 
approached to determine if they met eligibility criteria and determine their interest in 
participation. Patients who were receiving non-neurotoxic chemotherapy for any type of 
cancer were also identified through the list of patients kept in the infusion center. 
A convenience sample of 127 patients who had received at least one course of 
chemotherapy with paclitaxel, docetaxel, cisplatin, or oxaliplatin were recruited from the 
infusion centers. These patients were considered at high risk for chemotherapy induced 
peripheral neuropathy. An additional 40 cancer patients who had not received 
chemotherapy with paclitaxel, docetaxel, cisplatin, or oxaliplatin, and who were at low 
risk of chemotherapy induced peripheral neuropathy, were recruited. Patients who were 
receiving their first treatment with paclitaxel, docetaxel, cisplatin, or oxaliplatin on the 
day of the interview and had never received any other forms of neurotoxic chemotherapy 
were included in this group of 40 patients because they had not yet had time to develop 
neurotoxicities. 
Patients were approached by the researcher and informed of study requirements 
and risks and benefits of taking part in the study. If they agreed to participate, informed 
consent was obtained. The researcher asked the participants all items on the demographic 
form, the CIPNAT, and the Functional Assessment of Cancer Therapy/Gynecologic 
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Oncology Group-Neurotoxicity questionnaire (FACT&GOG-Ntx) and recorded their 
verbal responses on a questionnaire form. Questionnaires were orally administered at the 
time of consent while patients were in their private chemotherapy suites. If patients 
preferred to complete the questionnaires independently, they were permitted to do so. 
Thirty of the participants on neurotoxic chemotherapy were asked to complete a second 
CIPNAT for test-retest reliability over the phone 24-72 hours after chemotherapy or in 
person if they would be coming back to the site during that time. If they agreed, they 
were asked for a phone number where they could be contacted and an appointment time 
for the phone interview was mutually agreed upon. The provided phone number was kept 
on a separate log which contained only their subject number, phone number, appointment 
date and time, and whether the investigator was able to contact them for the interview.  
Phone numbers were deleted from the log, once the second set of questionnaires had been 
completed. If the researcher was unable to contact the participant at the provided phone 
number within seven days of completing the first set of questionnaires, the phone number 
was deleted from the log and no further attempts to contact that participant were made. 
Evaluating validity. Validity testing is necessary to ensure that an instrument 
measures what it is intended to measure (Waltz, Strickland, & Lenz, 2005). Content 
validity was assessed in the phase II study. In this phase III study, three techniques were 
used to evaluate construct validity. First, the instrument was administered to a group of 
cancer patients at high risk for neuropathic symptoms as well as to a comparison group of 
cancer patients who were at low risk for neuropathic symptoms. The results were 
compared using t-tests to determine whether scores of the two groups differed
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significantly on total scores. Significant differences between one group expected to have 
high scores on the CIPNAT and another group expected to have low scores on the 
CIPNAT provided evidence of validity. 
Correlation with a measure of the same or similar concept was also provided 
evidence of validity. The questionnaire was administered to a group of cancer patients 
along with an instrument purported to measure similar concepts, the neurotoxicity scale 
of the FACT&GOG-Ntx (Huang et al., 2007). Pearson’s correlations were used to 
evaluate correlations between the CIPNAT and the FACT/GOG-Ntx and provided
additional evidence of construct validity. Moderate to high correlations between the 
CIPNAT and the neurotoxicity scale of the FACT&GOG-Ntx were expected. 
Confirmatory factor analysis was performed using data from the 127 patients who 
have received neurotoxic chemotherapy to confirm the factor structure and provide 
further evidence of construct validity. It was hypothesized that factor analysis of the 
symptom experience scale would indicate that the CIPNAT symptom experience scale 
measures two underlying latent constructs: painful symptoms and non-painful symptoms. 
An alternative hypothesis was that the factor analysis would confirm two latent constructs 
of sensory symptoms and motor symptoms. The interference with usual activities scale 
was hypothesized to measure a single underlying latent construct, interference with daily 
activities.
Evaluating reliability. Reliability refers to how consistently an instrument assigns
scores to subjects (Waltz et al., 2005). Reliability for the instrument was evaluated by 
using the test-retest procedure. Neuropathy is conceptualized as relatively stable over a 
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short period of time for participants actively receiving chemotherapy and for a longer 
time frame for persons not on chemotherapy. Scores from test to retest are expected to be 
highly correlated. Because some neuropathic symptoms may be most noticeable in the 
first 24-72 hours after chemotherapy, patients who are getting neurotoxic chemotherapy 
completed the second CIPNAT by telephone approximately 24-72 hours after the first set 
of questionnaires was administered. If the patients were to be returning to the clinic
within 24-72 hours, the researcher met them there for the purpose of having them 
complete the second set of questionnaires. Patients who had difficulty writing due to 
CIPN had each item read to them so they could respond verbally, with the researcher 
recording their responses. Internal consistency reliability was evaluated using Cronbach’s 
alpha. Because the instrument was designed to measure more than one concept, alpha 
levels were determined for each scale, subscale, and for the entire instrument.
Data analysis. Data were analyzed using Statistical Package for the Social 
Sciences (SPSS) version 16. Factor analysis were conducted using both SPSS v. 16 and 
LISREL 8.0. The data was entered into SPSS and examined for data entry errors. 
Descriptive statistics were analyzed. Exploratory factor analysis was conducted in SPSS 
and confirmatory factor analysis was conducted in LISREL for the purpose of identifying 
the factor structure for the symptom experience scale and the symptom interference scale. 
Correlations and differences between means also were used to evaluate validity. 
Correlations were used to evaluate test-retest reliability. Internal consistency reliability of 
the symptom experience scale and the interference scale were evaluated using 
Cronbach’s alpha. Standardized alpha coefficients allow for comparison between data 
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collected using two different instruments using the same group of participants 
(Alsawalmeh & Feldt, 2000). Standardized alpha coefficients between the CIPNAT and 
FACT-Ntx were compared.
Results
Demographics. There were 127 participants in the group receiving neurotoxic 
chemotherapy and 40 participants in the comparison group. Ages ranged from 19 to 80
with a mean age of 58. Sixty percent of participants were female and 40% were male. 
The majority were Caucasian, married and either retired or disabled (Table 6). Twenty-
seven percent continued to work on a part-time or full-time basis. Participants had a 
diverse range of incomes and educational backgrounds. Almost all participants had solid 
tumors. Breast, lung, or colon cancers were the most frequently occurring sites. Most had 
stage 3 or 4 disease. From the patients in the group who were on treatment with 
neurotoxic chemotherapy, approximately 30% were receiving paclitaxel, 31% were
receiving docetaxel, 27% were receiving oxaliplatin and 13% were receiving cisplatin.
They had received from 1 to 30 treatments with a mean of 5.2 treatments and had 
received an average of 500mg/m2 of neurotoxic drug. 
Descriptive symptom data. In the group receiving neurotoxic chemotherapy, cold 
sensitivity and muscle/joint aches were the symptoms which were most often reported, 
followed by numbness in the hands, numbness in the feet, trouble with balance, muscle 
weakness, tingling in the hands, tingling in the feet and nerve pain. Nerve pain was the 
most severe symptom. Muscle/joint aches were the most distressing symptom. Numbness 
in the feet was the symptom that patients reported as most constant, or frequently 
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occurring (Table 7). It should be noted that 14.17% (n=18) of patients receiving 
neurotoxic chemotherapy reported no neurotoxicity symptoms. 
Frequencies for the symptom interference items show that neuropathic symptoms 
interfered with enjoyment of life, sleep and chores in more than half of participants being 
treated with neurotoxic chemotherapy. Neuropathic symptoms interfered with walking, 
exercise and hobbies in 48% of participants. Neuropathic symptoms also interfered with 
working, picking up objects, writing, holding onto objects, relationships, driving, 
dressing and sexual activity(Table 8).
Twenty- two percent (n=28) had experienced injuries as a result of neuropathic 
symptoms. The majority of injuries were falls (n=21) or injuries caused by bumping into 
things (n=4). Pulled back muscle (n=1), poor wound healing (n=1) and acute 
hypersensitivity reaction (n=1) were reported but were not thought to be related to 
neuropathic symptoms. Ninety two percent (n=23) of patients reporting falls or bumping 
into things also reported loss of balance.
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Table 6. Frequencies and Percentages of Demographic Data   
                                                                                                         Neurotoxic chemo n=127          comparison n=40                                                                        
Demographic Data Frequency Percent Frequency Percent
Marital status single 14 11 4 10
married 82 64.6 24 60
divorced 16 12.6 5 12.5
separated 3 2.4 1 2.5
widowed 12 9.4 6 15
Income less than 25K 30 23.6 7 17.5
25-50K 26 20.5 10 25
50-75K 19 15 10 25
over 75K 26 20.5 9 22.5
prefer not to answer 26 20.5 3 7.5
Missing data 0 0 1 2.5
Education 8-12 years 43 33.9 18 45
13-14 years 36 28.3 11 27.5
15-16 years 33 26.0 7 17.5
17-23 years 13 10.4 4 10
Missing Data 2 1.6 0 0
Race/Ethnicity American Indian/Alaskan 
Native
2 1.6
1 2.5
Asian 2 1.6 1 2.5
African American 7 5.5 2 5
Hispanic 8 6.3 2 5
White/Caucasian 108 85 34 85
Employment full time 28 22 8 20
part time 5 3.9 3 7.5
on leave of absence 15 11.8 2 5
retired 44 34.6 16 40
disabled 25 19.7 10 25
full-time student 1 0.8 0 0
unemployed 7 5.5 1 2.5
self-employed 2 1.6 0 0
Cancer Type breast 26 20.5 16 40
lung 20 15.7 15 37.5
colon 33 26 4 10
gynecologic malignancies 10 7.8 1 2.5
Other solid tumors 37 29.1 3 7.5
Hematologic malignancies 1 0.8 0 0
Cancer Stage 1 4 3.1 2 5
2 15 11.8 6 15
3 37 29.1 15 37.5
4 62 48.8 10 25
Extensive small cell lung 2 1.6 4 10
Limited small cell lung 0 0 1 2.5
Missing 7 5.5 2 5
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Table 7: Occurrence, severity, intensity, distress and timing of neuropathic symptoms
Symptom n Percent
  mean 
severity SD mean distress SD mean timing SD
Cold Sensitivity 66 51.97 5.17 2.79 4.26 3.26 5.61 2.69
Muscle or joint 
aches
66 51.97 6.02 2.69 5.74 2.85 5.42 2.79
Numb hands 63 49.60 4.00 2.34 3.43 2.94 6.49 3.04
Numb feet 60 47.24 4.97 3.00 4.08 3.40 7.37 3.08
Loss of Balance 59 39.37 4.66 2.67 4.95 3.04 5.42 2.37
Muscle Weakness 58 45.70 5.66 2.71 5.50 3.42 5.89 2.61
Tingling hands 56 44.09 4.04 2.52 3.91 3.00 6.20 3.08
Tingling Feet 48 37.80 4.25 2.73 3.88 3.13 6.50 3.05
Nerve Pain 29 22.83 6.48 3.03 5.69 3.26 5.28 2.66
Table 8: Frequency of interference items
Interference item n Percent mean SD Range
Enjoyment of Life 71 55.90 5 3 1-10
Sleep 69 54.33 6 3 1-10
Chores 65 51.18 5 3 1-10
Hobbies 61 48.03 5 3 1-10
Walking 60 47.24 5 3 1-10
Exercise 60 47.24 6 3 1-10
Working 47 37.00 7 3 1-10
Picking up objects 47 37.00 5 3 1-10
Writing 44 34.65 5 3 1-10
Holding onto objects 42 33.07 4 2 1-10
Relationships 40 31.50 4 2 1-10
Driving 39 30.70 5 3 1-10
Dressing 38 29.92 4 3 1-10
Injuries 28 22.05 N/A N/A Yes/no
Sexual Activity 26 20.47 5 3 1-10
Validity. Differences between patients expected to have symptoms of neurotoxity 
and those not expected to have neurotoxicity were compared using t-tests for unequal 
variances. Independent t-tests for unequal variance were used because Levene’s test for 
equality of variance indicated that variance between the two groups were different (Table 
9). Scores on the CIPNAT as well as the FACT-Ntx demonstrated significant difference 
between these two groups (Table 9). Correlation with a measure of the same concept
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indicated that scores between the CIPNAT and the FACT-Ntx were strongly correlated (r 
=.73, p=.000, n=127), supporting construct validity of the CIPNAT.
Table 9. Independent t-tests for CIPNAT and FACT/GOG-Ntx.
Instrument group
Levene’s test for 
unequal 
variance
               F P N
         
Mean SD P
CIPNAT
neurotoxic 
chemo 15.55 .000 126
       
142.62
   
103.00
               
.000
comparison 40
         
33.04
     
59.22
Symptom experience
neurotoxic 
chemo 23.28 .000 127 110.86 80.85 .000
scale comparison 40 22.34 40.37
Interference scale
neurotoxic 
chemo 11.11 .000 126 29.29 27.87 .000
comparison 40 9.95 19.98
FACT/GOG-NTX
neurotoxic 
chemo 16.35 .000 127 9.77
       
7.55 .000
comparison 40 3.35 4.00
Confirmatory factor analysis was based on the covariance matrix and used 
maximum likelihood estimation. Confirmatory factor analysis of the nine items from the 
symptom experience scale indicate that the model representing painful and non-painful 
symptoms had  poor goodness of fit (Table 11) and factor loadings on several items were 
low (Table 10). The model representing sensory and motor symptoms had a better fit 
(Table 11) and higher factor loadings (Table 10). Numbness in hands, numbness in feet, 
tingling in hands, tingling in feet, cold sensitivity, and nerve pain loaded on the sensory 
factor. Muscle or joint aches, muscle weakness, and loss of balance loaded on the motor 
factor (Table 10). The model explained from fifteen to 56% of item variance. Evaluation 
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of modification indices suggested that error terms in the theta delta matrix were highly 
correlated, especially for numbness and tingling in the hands and numbness and tingling 
in the feet, reducing the goodness of fit of the measurement model (Table 11). When 
error terms for numbness in the hands and tingling in the hands as well as numbness in 
the feet and tingling in the feet were allowed to correlate, the fit of the model improved.
Table 10. CFA Factor loadings and squared multiple correlations.
Symptom Non-Painful Painful R2
Numb Hands 0.733 - - .538
Numb Feet   0.649 - - .421
Cold Sensitivity 0.364 - - .133
Muscle Weakness  0.341 - - .116
Trouble with Balance 0.340 - - .115
Tingling Hands - - 0.671 ..450
Tingling Feet - - 0.644 .414
Nerve Pain - - 0.367 .135
Muscle/joint Aches - - 0.291 .085
Symptom Sensory  Motor R2
Numb Hands 0.678 - - .459
Numb Feet   0.640 - - .409
Tingling Hands 0.608 - - .370
Tingling Feet 0.612 - - .375
Cold Sensitivity 0.389 - - .152
Nerve Pain 0.392 - - .154
Muscle/joint Aches - - 0.504 .254
Muscle Weakness  - - 0.631 .398
Trouble with Balance - - 0.746 .557
Activity Manual dexterity
General
activities R2
Dressing .731 - - .534
Writing .596 - - .355
Picking up objects .873 - - .760
Holding onto objects .844 - - .715
Driving - - .569 .321
Working - - .579 .344
Hobbies - - .704 .503
Exercise - - .728 .540
Sex - - .317 .103
Sleep - - .626 .395
Relationships - - .647 .419
Walking - - .774 .592
Chores - - .871 .748
Enjoyment of life - - .795 .645
Injuries - - .390 .152
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Table 11. Goodness of fit indices.
Scale df X2 RMSEA GFI CFI NFI
2 factor model 
Painful/non-painful
Symptom experience
26 110.28 .162 .836 .764 .720
2 factor model , 
sensory/motor
Symptom experience
26 70.29 .106 .90 .898 .842
2 factor model with 
correlated error terms
Symptom experience
sensory/motor
24 47.733 .086 .924 .938 .884
Interference 
2 factor solution
89 267.68 .119 .792 .928 .893
Interference 
2 factor solution with
sex and injury removed
64 141.90 .098 .853 .957 .925
Confirmatory factor analysis of the fifteen items from the interference scale also 
revealed two underlying latent concepts, activities requiring manual dexterity and general 
activities. Dressing, picking up objects, holding onto objects and writing loaded on the 
manual dexterity subscale. Walking, driving, working, participating in hobbies, 
exercising, sexual activity, sleeping, relationships with other people, doing household 
chores, and enjoyment of life all loaded on the general activities factor. This model 
explained 32-76% of item variance with the exception of two items (Table 10). Only 10% 
of the variance in sexual activity was explained by the model. About 15% of the variance 
in injuries from neuropathic symptoms was explained by the model. When sexual activity 
and occurrence of neuropathy related injuries were removed from the model, the 
goodness of fit of the model improved significantly (Table 11). Again, error terms were 
highly correlated, reducing the goodness of fit of the model. Modification indices 
suggested that error terms for “work” and “hobbies or leisure activities” as well as for 
“picking up things” and “holding onto things” were highly correlated.
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Reliability . The CIPNAT and FACT-Ntx were administered to a subset of 30 
patients for test-retest reliability. Test-retest scores on the symptom experience scale 
(r=.897, p=.000) and the interference with activities scale (r=.932, p=.000) show that 
scores at time one and time two were highly correlated. Correlations for the FACT-Ntx 
were slightly lower (r=.828, p=.000) than for either scale of the CIPNAT. 
Cronbach’s alpha for the total CIPNAT, the symptom experience scale and its 
subscales, the interference scale and its subscales all demonstrated internal consistency 
reliability of the CIPNAT (Table 12). Item to total correlations ranged from .249-.688 
(Table 13). Cronbach’s alpha coefficients are dependent on test length as well as item 
variance (Waltz, Strickland, & Lenz, 2005). Standardized alpha values can be adjusted 
using the Spearman-Brown formula to allow for comparison of independent alpha 
coefficients between scales of different lengths (Alsawalmeh & Feldt, 1999). The alpha 
coefficient for the CIPNAT, adjusted using the Spearman-Brown formula, is estimated at 
.813 if it were reduced to an 11 item scale. Similarly, if the FACT/GOG-Ntx were 
lengthened to include 55 items, the estimated alpha is .948. Differences between these 
values were not significant indicating that the CIPNAT and the FACT/GOG-Ntx have 
comparable internal consistency reliability. 
Table 12. Cronbach’s alpha for CIPNAT and FACT-Ntx
Scale n n of items alpha standardized alpha
CIPNAT 125 55 .945 .956
CIPNAT symptom experience 126 40 .927 .947
   Sensory subscale 126 28 .921 .945
   Motor subscale 127 12 .890 .924
CIPNAT interference 126 15 .894 .897
   Manual Dexterity subscale 126 4 .827 .832
   General Activity subscale 126 11 .871 .869
FACT/GOG-Ntx 127 11 .784 .784
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Discussion
The findings of this study support use of the CIPNAT as a reliable and valid self-
report tool for CIPN.  It provides a comprehensive instrument for assessment of CIPN 
that addresses multidimensional elements including character, timing, intensity, distress 
and interference with activities. The CIPNAT is a useful tool for clinicians and 
researchers interested in the effects of CIPN on performance. 
Validity. Validity evaluation including use of the contrasted groups approach, 
correlation with the FACT/GOG-Ntx and confirmatory factor analysis indicate that the 
CIPNAT is valid for assessing effects of neuropathy in cancer patients receiving 
chemotherapy. Differences between groups and correlation with the FACT/GOG-Ntx 
indicate that validity of the CIPNAT is strong.
The factor structure of the CIPNAT was different than hypothesized. It was 
expected that factor analysis of neuropathic symptoms would reveal two factors; either
painful symptoms and non-painful symptoms or sensory symptoms and motor symptoms. 
The findings of this study support a two factor structure; sensory symptoms and motor 
symptoms. Examination of factor loadings in exploratory analysis favored selection of 
sensory symptoms and motor symptoms over painful symptoms and non-painful 
symptoms. 
It also was expected that the interference subscale would consist of a single 
underlying construct. The findings of this study do not support a single factor solution but 
suggest that two factors, general activities and activities requiring manual dexterity, make 
up the interference scale. These findings are similar to those of Almadrones and 
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colleagues (2004) who reported that general mobility and specific mobility were the 
underlying factors of the Peripheral Neuropathy Scale functional performance subscale.
The findings highlight the importance of evaluating the impact of neuropathic symptoms 
on both specific activities as well as on general activities that can affect individual quality 
of life. The presence of a sensory symptom subscale and a motor symptom subscale 
support the idea that muscular symptoms are an important aspect of CIPN and should be 
included in routine assessment of CIPN. 
Reliability. The results of this study indicate that the CIPNAT is a highly reliable 
tool for evaluation of CIPN. Test-retest reliability evaluation reveals very strong 
reliability. Internal consistency reliability also indicate that the CIPNAT is highly reliable 
and internally consistent, meaning answers to one item are a good indication of answers 
on other items (Waltz, Strickland, & Lenz, 2005).  Test-retest and internal consistency 
reliability were comparable to the FACT/GOG-Ntx.
Revisions to the CIPNAT. Validity and reliability information obtained in this 
phase III study guided further revisions to the CIPNAT. The items pertaining to “nerve 
pain” were revised to refer to “discomfort in the hands” and “discomfort in the feet” in an 
effort to help differentiate between neuropathic pain related to chemotherapy and pain 
related to other causes. 
The amount of variance explained in nerve pain and cold sensitivity combined with low 
factor loadings for these variables suggest that these symptoms have other causes outside 
of CIPN (Kelloway, 1998) and may warrant further evaluation. 
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Numbness and tingling in the hands will be evaluated on the same page and 
numbness and tingling in the feet will be evaluated on the same page to minimize 
confusion and redundancy.  Numbness in the hands and tingling in the hands are highly 
correlated as are numbness in the feet and tingling in the feet. These correlations caused 
problems with goodness of fit in confirmatory factor analysis. Numbness and tingling 
often co-occur (Ocean & Vahdat, 2004) and therefore patients may not be able to 
differentiate between the two. Feedback from patients during data collection supports this 
idea. Items on the CIPNAT were revised accordingly.
The item asking about interference with sexual activity will be eliminated because 
of low factor loadings as well as low item-total correlations and low occurrence.  The 
item asking about injuries will be rephrased to ask about falls and will be included as part 
of further assessment of loss of balance. In addition, assessment of loss of balance will 
include asking patients if they use a walker or cane. Possible responses for this item will 
include “no”, “yes, I used a cane or walker before I started chemo, or “yes, I started using 
a cane or walker since starting chemo”. Both of these new items will be considered 
descriptive data and will not be included in scoring the CIPNAT. 
Scoring of the CIPNAT. The resulting CIPNAT (v.1) is a 64 item self report tool 
with 51 items in the symptom experience scale and 13 items in the interference scale 
(Appendix F). Because a simplified scoring technique is desirable, scores on intensity, 
distress, and frequency will be summed to form a symptom experience scale score. 
Symptom experience scale scores may range from 0-240. Scores on the interference will 
be summed to form a total interference scale with a range of 0-130. Total scores for the 
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entire instrument range from 0-370. Higher scores correspond with more CIPN and more 
neuropathic interference with activities. 
Limitations. Although the results of this study indicate that the CIPNAT is a 
reliable and valid self-report tool for CIPN, several limitations should be acknowledged. 
The sample size was not large, which may have had some impact on the results. Patients 
were predominantly from a large comprehensive cancer center in an urban area. Although 
this is a tertiary referral center, it serves a distinct geographic region, so the results may 
not be generalizable to other populations. 
Confirmatory factor analysis using dichotomous variables is a controversial but 
widely implemented technique (Muthen, 1978). Tetrachoric correlation is an advanced 
technique used in factor analysis of dichotomous variables involving large sample sizes. 
Because this sample was small, it was not possible to use this technique. Our analysis 
may have been affected by not using tetrachoric correlations for factor analysis of the 
symptom experience subscale.
Implications for nursing. Assessment and management of side effects of 
chemotherapy, including CIPN, is predominantly a nursing responsibility. Unfortunately, 
nurses have not had access to good assessment tools for CIPN (ONS, 2005). This study 
provides an instrument that may be useful for clinical assessment of CIPN. 
Effective prevention and treatment for CIPN is virtually non-existent. The best 
available treatment for CIPN is to stop chemotherapy or reduce the dose (ONS, 2005); 
however, this may lead to higher cancer morbidity and mortality. Sometimes less 
neurotoxic chemotherapy drugs are available but they are not always as effective in 
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treating the underlying cancer.  In all patients, particularly those with advanced or 
incurable disease, discussions about possible effects of neurotoxic chemotherapy, 
including impaired physical functioning and enjoyment of life should occur prior to 
initiation of chemotherapy.  Evaluation of personal goals and lifestyle should guide 
treatment planning. Oncology nurses are integral to helping patients understand the 
potential neurotoxic side effects of chemotherapy and how these side effects may affect 
the patient’s daily activities.
Nurses who are not directly involved with patients on chemotherapy may be 
unaware of symptoms of CIPN or how it potentially affects performance and quality of 
life. Attention to educating nurses about CIPN is critical because symptoms can last for 
many years after cessation of chemotherapy, making it a survivorship issue that must be 
addressed in research, education, and clinical practice.
Directions for future research. It is the goal of the author to develop and test a 
computerized version of the CIPNAT. This would help minimize missing data, allow for 
automatic scoring and reduce patient burden. Following development and validation of 
the computerized version of the CIPNAT, a computer based system for self-management 
of CIPN will be developed. Both the pen and pencil version and the computerized version 
of the CIPNAT will be used to test interventions aimed at decreasing neuropathic 
symptoms and/or minimizing neuropathic interference with performance status. 
Conclusions. The results of this study confirm that the CIPNAT is a reliable and 
valid measure of CIPN in cancer patients receiving chemotherapy. The CIPNAT is more 
comprehensive than previously published instruments because it takes into account the 
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multidimensional aspects of CIPN including character, intensity, timing, distress and 
interference with activities. An additional advantage of the CIPNAT is its strong data for 
reliability and validity. This study supports earlier research indicating that neurotoxic 
chemotherapy drugs produce both sensory and motor effects (Postma, et al. 2005; Huang, 
2007). It also supports earlier research indicating that CIPN significantly interferes with 
patients’ ability to perform specific tasks requiring manual dexterity as well as general 
activities including enjoyment of life (Almadrones, et al., 2005). 
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Appendix A. FACT/GOG-Ntx Version  4.
By circling one (1) number per line, please indicate how true each statement has 
been for you during the past 7 days.
Not at 
all
A 
little 
bit
Some-
what
Quite
 a bit
Very 
much
NTX
1
I have numbness or tingling in my 
hands ................................................................
0 1 2 3 4
NTX
2
I have numbness or tingling in my 
feet................................................................
0 1 2 3 4
NTX
3
I feel discomfort in my hands ................................0 1 2 3 4
NTX
4
I feel discomfort in my feet................................0 1 2 3 4
NTX
5
I have joint pain or muscle cramps ................................0 1 2 3 4
HI
12
I feel weak all over................................ 0 1 2 3 4
NTX
6
I have trouble hearing ................................0 1 2 3 4
NTX
7
I get a ringing or buzzing in my ears ................................0 1 2 3 4
NTX
8
I have trouble buttoning buttons ................................0 1 2 3 4
NTX
9
I have trouble feeling the shape of 
small objects when they are in my 
hand................................................................
0 1 2 3 4
An6 I have trouble walking ................................0 1 2 3 4
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Appendix B. CIPNAT
Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT)
Chemotherapy induced peripheral neuropathy occurs with certain types of chemotherapy 
that affect the nervous  system. The following questions are designed to help us learn 
more about any symptoms of chemotherapy induced peripheral neuropathy that you 
might be experiencing. We are particularly interested in learning about symptoms that 
you have developed since receiving chemotherapy.
For pages 1-9 first read the question at the top of the page. If you answer yes than answer 
the rest of the questions on the page. If you answer no, skip to the next page. If you had 
the symptom before starting chemotherapy and there has been no change, answer no and 
move to the next page.
For page 10-11, if you have answered yes to any of the questions on the previous pages 
then circle a number 0-10 that corresponds with how much the symptoms you reported 
are interfering with your ability to perform certain activities. If you do not normally 
participate in the activity listed, please respond by circling 0. If you answered no to the 
first question on each previous page, you do not need to complete pages 10-11.
Please answer every question that applies to you.
 If you have physical problems that prevent you from being able to write, someone will 
read the questions to you and ask for your responses. If it is easier for you, someone else 
on the research team or a family member or friend can ask you the questions on the 
survey. We have tried to make it as brief and easy to complete as possible. If you get tired 
please feel free to take a break and come back to it later.
The information you provide is invaluable to us. Thank you.
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Appendix B (continued)
1 A.  Since starting chemotherapy, have you developed numbness in your hands ? 
(circle one)      
a. No   (go to the next page)           
b. Yes     (answer the questions below)  
1 B. How much of the hands are numb? (circle one)  
a. Fingertips only   
b. Fingertips and fingers   
c. Entire hands  
d. Entire hands and portions of the 
arms
1 C. At its worst, how severe is the numbness in the hands? (circle one)
 0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 1 D. At its worst, how distressing is the numbness in the hands? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
1 E. How often do you have numbness in the hands? (circle one)
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
1 F. When is the numbness in the hands most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting chemotherapy, for 
______days
      f.    Not applicable
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Appendix B (continued)
2 A. Since starting chemotherapy, have you developed numbness in the feet ? (circle 
one)           
a. No   (go to the next page)      
b. Yes   (answer the questions below)  
2 B. How much of the foot is numb? (circle one)
a. Toes only                         
b. Toes and balls of feet                                      
c. Toes, balls of feet, and sole of 
foot
d. Entire foot                                  
e. Entire foot/ parts of the leg
2 C. At its worst, how severe is the numbness in the feet? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 2 D. At its worst, how distressing is the numbness in the feet? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
                                                                                                            
2 E. How often do you have the numbness in the feet? (circle one)
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
2 F. When is the numbness in the feet most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting chemotherapy, for 
______days
      f.    Not applicable
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Appendix B (continued)
3 A. Since starting chemotherapy, have you developed tingling in the hands? (circle 
one)              
a. No    (go to the next page)      
b. Yes    (answer the questions below)  
3 B. How much of the hands tingle? (circle one)  
a. Fingertips only
b. Fingertips and fingers   
c. Entire hands  
d. Entire hands and portions of 
the arms
3 C. At its worst, how severe is the tingling in the hands? (circle one)  
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 3 D. At its worst, how distressing is the tingling in the hands? (circle one)  
 0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
3 E. How often do you have tingling in the hands? (circle one)  
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
3 F. When is the tingling in the hands most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting chemotherapy, for 
______days
      f.    Not applicable
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Appendix B (continued)
4 A. Since starting chemotherapy, have you developed tingling in the feet? (circle 
one)         
a. No   (go to the next page)
b. Yes   (answer the questions below)       
4 B. How much of the feet tingle? (circle one)  
a. Toes only                         
b. Toes and balls of feet                                         
c. Toes, balls of feet, and sole of 
foot
d. Entire foot                                  
e. Entire foot/ parts of the leg
4 C. At its worst, how severe is the tingling in the feet? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 4 D. At its worst, how distressing is the tingling in the feet? (circle one)
 0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
4 E. How often do you have the tingling in the feet? (circle one)  
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
4 F. When is the tingling in the feet most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e.   After getting chemotherapy, for          
_____days     
      f.    Not applicable
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Appendix B (continued)
5 A. Since starting chemotherapy, have you developed sensitivity to cold 
temperatures? (circle one)
a. No   (go to the next page)   
b. Yes   (answer the questions below)       
5 B. What part(s) of your body are sensitive to cold? (circle as many as apply)
a.  Hands   
b.  Arms
c.  Feet
d.  Legs
e.  Back
f.  Abdomen        
g.  Throat   
h.  Jaw  
i.  Mouth
j.  Whole body
    
5 C.  At its worst, how severe is the cold sensitivity? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 5 D. At its worst, how distressing is the cold sensitivity? (circle one)
 0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
5 E. How often do you have the cold sensitivity? (circle one)  
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
5 F. When is the cold sensitivity most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting chemotherapy, for 
______days
      f.    Not applicable
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Appendix B (continued)
6 A. Since starting chemotherapy, have you had nerve pain (i.e. burning, shooting, 
stabbing, electric-like sensations)? (circle one)           
a. No   (go to the next page)      
b. Yes   (answer the questions below)  
6B. What part(s) of your body have nerve pain? (circle as many as apply)
a. Hands    
b. Arms      
c.  Feet    
d.  Legs
e. Jaw  
f. Neck
g. Other__________________
6 C. At its worst, how severe is the nerve pain? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 6 D. At its worst, how distressing is the nerve pain? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
6 E. How often do you have the nerve pain? (circle one)
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
6 F. Circle the words that describe your nerve pain? (circle as many as apply)
a. Sharp 
b. Shooting 
c. Burning 
d. Electric-like 
e. Stabbing 
f. Pins and needles 
g. other______________________
6 G. When is the nerve pain most severe?(circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d.    Nights
e.    After getting chemotherapy, for   
______days        
      f.    Not applicabl
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7 A. Since starting chemotherapy, have you developed muscle or joint aches? (circle 
one)
a. No (go to the next page)
b. Yes (answer the questions below)     
7 B. What part(s) of your body ache? (circle as many as apply)
a. Muscles 
b. Joints 
c. Hands
d. Arms
e. Feet
f. Legs  
g. Back  
h.  Whole body
7 C. At its worst, how severe is the aching? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
 7 D. At its worst, how distressing is the aching? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
                                    
7 E. How often do you have aching? (circle one)  
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
7 F. When is the aching most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting chemotherapy, for 
______days
      f.    Not applicable
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8 A. Since starting chemotherapy, have your arms/hands or legs/feet felt weak? 
(circle one)    
a. No    (go to the next page)
b. Yes    (answer the questions below)       
8 B. What part(s) of your body have felt weak? (circle as many as apply)
a. Hands
b. Arms
c. Feet
d. Legs  
    
8 C. At its worst, how severe is the weakness? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
8 D. At its worst, how distressing is the weakness? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
8 E. How often do you have weakness in the arms/hands or legs/feet? (circle one)  
0           1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
8 F. When is the weakness most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e. After getting 
chemotherapy,for______days
      f.    Not applicable
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9 A. Since starting chemotherapy, have you had trouble with your balance? (circle 
one)
a. No    (go to the next page)
b. Yes    (answer the questions below)   
    
9 B. At its worst, how severe is the trouble with your balance? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not   Moderately                                             Extremely 
At all                                                        Severe                                                       Severe
Severe
9 C. At its worst, how distressing is the trouble with your balance? (circle one)
0           1           2           3           4            5            6            7            8            9             10
Not                    Moderately                             Extremely 
At all                                                                        Distressing                           Distressing
Distressing
9 D.  How often do you have trouble with your balance?  (circle one)
0          1            2             3           4           5            6            7            8           9            10
never              monthly               weekly                 daily                  hourly               always 
9 E. When is the trouble with your balance most severe? (circle as many as apply)
a. Mornings
b. Afternoons
c. Evenings
d. Nights
e.   After getting chemotherapy, for   
______days     
      f.    Not applicable
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If you answered yes to any of the previous symptoms, how much are your symptoms 
interfering with:
10 A. Dressing (buttoning, zipping, etc)     0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 B. Walking                                             0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 C. Picking up                                        0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
                    
10 D. Holding onto objects                        0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
                                                         
10 E. Driving                                               0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 F. Working                                            0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 G. Participating in hobbies/                  0    1     2     3     4     5     6     7     8     9     10
           leisure activities                              Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 H.  Exercising                                       0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
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10 I. Sexual Activity                                   0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 J.  Sleeping                                            0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
                                                                                                                        
10 K. Relationships with other people       0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 L. Writing                                              0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
  
10 M. Usual household                               0    1     2     3     4     5     6     7     8      9     10
                                            Not             Moderately                    Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
10 N. Enjoyment of  life                             0    1     2     3     4     5     6     7     8      9     10
                                            Not               Moderately                   Completely
                                                                                 At all                         Interfering                      Interfering                      
                                                                                 Interfering
       
Have you had any bodily injuries (even minor) because of the symptoms you have 
reported as part of this survey (numbness, weakness, problems with balance, etc)?
No                   Yes,  describe_______________________________________________
Thank you for your time
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Appendix C. Demographic Data Form
Page one to be completed by participant.
1. What is your current age?__________
2. Which gender are you (circle one)?    Male Female
3. What is your marital status (check one)?
____single
____married
____divorced
____separated
____widowed
4. What is your annual household income (check one)?
____ less than 24,999 dollars per year
____25,000-49,999 dollars per year
____50,000-74,999 dollars per year
____more than 75,000 dollars per year
____prefer not to answer
5. How many years of formal education have you completed?________
Example: 12 = high school graduate 14 = associate degree or technical school 
16 = baccalaureate degree
6. What is your race or ethnicity (check all that apply)
___American Indian/Alaskan Native
___Asian
___African American
___Hispanic
___Native Hawaiian/Pacific Islander
___White/Caucasian
___other or unknown
7. What is your current employment status (check one):
___full time employee 
___part time employee
___on leave of absence
___retired
___ disabled
___ full time student
85
Appendix  C (continued)
To be completed by researcher:
8. Type of cancer (circle one) :   breast lung colon
9. Stage of cancer________
10. Type of chemotherapy receiving (check all that apply) 
___paclitaxel
___docetaxel
___ cisplatin
___oxaliplatin
11. Cycle Number______
12. Cumulative doses 
Drug_________dose__________mg/m2
Drug_________dose__________mg/m2
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Appendix D. Moffitt SRC Approval Letter
Wednesday, July 09, 2008 
Cindy Tofthagen, MS, ARNP, AOCNP 
Moffitt Cancer Center 
University of South Florida 
12902 Magnolia Drive 
Tampa, FL 33612 
Dear Dr. McMillan: 
The Behavioral Scientific Review Committee (SRC) has approved your research protocol 
dated 7/2/2008 entitled, “Psychometric Evaluation of the Chemotherapy Induced 
Peripheral Neuropathy Assessment Tool” (MCC 15639) for use at the Moffitt Cancer 
Center under the Center’s expedited review policy pending approval of the Institutional 
Review Board (IRB) and satisfaction of institutional operational and financial review 
requirements. Please be aware that after you receive IRB approval, you must submit a copy 
of the IRB approval letter to the Protocol Review and Monitoring System and request study 
activation before you commence any study activities. The Protocol Review and Monitoring 
System will ensure that all applicable institutional reviews have been completed. You will 
then be issued an activation letter. Upon receipt of the activation letter, you will be able to 
conduct your study. 
It is your responsibility to ensure that all Moffitt staff (Nursing, Pharmacy, Data 
Management, etc.) is informed and aware of the details of the project. The Scientific Review 
Committee encourages the use of in-services for those projects which are complex or require 
special attention. 
All changes made to protocols approved by the SRC must be submitted to the Protocol 
Review and Monitoring System. Substantial changes (i.e., scientific changes, therapy 
changes or eligibility changes) require SRC review and approval. 
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If this project is not being managed by the Protocol Review and Monitoring System, then it is 
your responsibility to follow through will all requirements of the IRB as listed on page 5 of 
the “Application for Approval of Investigation Involving the Use of Human Subjects USF 
Health Sciences Center IRB”. After the study is approved, the IRB requires submission of a 
continuing review report annually. Please forward a copy of this report to the Protocol 
Review and Monitoring System. 
Oncore is the Cancer Center’s mechanism for required submission and review of materials 
requiring IRB review as well as items requiring review by the Scientific Review and Protocol 
Monitoring Committees. If you are not currently reporting the necessary research activities, 
such as patient accrual, changes in procedure, adverse events, and continuing reviews in 
Oncore, please contact Jeryl Madden, Oncore Coordinator, at 745-6964 for direction. 
Sincerely, 
Paul Jacobsen, PhD 
Chair, Behavioral Subcommittee 
Scientific Review Committee
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Appendix E. Letter of approval, private practice.
July 10, 2008
To Whom it May Concern,
I have reviewed the research proposal by Cindy Tofthagen entitled Psychometric 
Evaluation of the Chemotherapy Induced Peripheral Neuropathy Assessment Tool. I find 
the research appropriate for my oncology patients and give the investigator permission to 
conduct research in this office. Appropriate resources are available for this research to be 
conducted, including a private room for consenting and interviewing patients. Based on 
the minimal risks associated with this research, adequate provisions are available to 
handle any unanticipated events. Thank you for your time and attention to this matter.
Ron D. Schiff, M.D., Ph.D.
Egberto Zayas, M.D.
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Appendix  F: CIPNAT (Version 1)
Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT)
Version 1
Chemotherapy induced peripheral neuropathy occurs with certain types of chemotherapy 
that affect the nervous system. The following questions are designed to help us learn 
more about any symptoms of chemotherapy induced peripheral neuropathy that you 
might be experiencing. We are particularly interested in learning about symptoms that 
you have developed since receiving chemotherapy.
For pages 1-8 first read the question at the top of the page. If you answer yes than answer 
the rest of the questions on the page. If you answer no, skip to the next page. If you had 
the symptom before starting chemotherapy and there has been no change, answer no and 
move to the next page.
For page 9-10, if you have answered yes to any of the questions on the previous pages 
then circle a number 0-10 that corresponds with how much the symptoms you reported 
are interfering with your ability to perform certain activities. If you do not normally 
participate in the activity listed, please respond by circling 0. If you answered no to the 
first question on each previous page, you do not need to complete pages 9-10.
Please answer every question that applies to you.
 If you have physical problems that prevent you from being able to write, someone will 
read the questions to you and ask for your responses. If it is easier for you, someone else 
on the research team or a family member or friend can ask you the questions on the 
survey. We have tried to make it as brief and easy to complete as possible. If you get tired 
please feel free to take a break and come back to it later.
The information you provide is invaluable to us. Thank you.
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1A.  Since starting chemotherapy, have you developed numbness or tingling in your 
hands? (circle one)      
a. No   (go to the next page)           
b. Yes     (answer the questions below)  
1B. Which do you have (circle one)?
a. Numbness
b. Tingling
c. Both numbness and tingling
1C. How much of the hands have numbness or tingling? (circle one)
a. Fingertips only
b. Fingertips and fingers   
c. Entire hands  
d. Entire hands and portions of the arm
1 D. At its worst, how severe is the numbness or tingling in the hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 1 E. At its worst, how distressing is the numbness or tingling in the hands? (circle 
one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
1 F. How often do you have numbness or tingling in the hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
1 G. Is the numbness or tingling in your hands worse after getting chemo ? (circle 
one)
a. No     
b. Yes, for how many days______
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2A. Since starting chemotherapy, have you developed numbness or tingling in your 
feet? (circle one)      
a.  No   (go to the next page)          
b. Yes     (answer the questions below)  
2B. Which do you have (circle one)?
a. Numbness
b. Tingling
c. Both numbness and tingling
2 C. How much of the feet tingle? (circle one)  
a. Toes only                         
b. Toes and balls of feet                                         
c. Entire foot                                  
d. Entire foot/ parts of the leg
2 D. At its worst, how severe is the numbness/tingling in the hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
2 E. At its worst, how distressing is the numbness in the hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
2 F. How often do you have numbness in the hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
2 G. Is the numbness or tingling in your hands worse after getting chemo? (circle 
one)
a. No     
b. Yes, for how many days______
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3 A. Since starting chemotherapy, have you had discomfort in your hands (circle 
one)?
a. No   (go to the next page)   
b. Yes   (answer the questions below)
3 B. At its worst, how severe is the discomfort in your hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 3 C. At its worst, how distressing is the discomfort in your hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
3 D. How often do you have the discomfort in your hands? (circle one)
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
3E. Circle the words that describe the discomfort in your hands? (circle as many as 
apply)
a. Sharp 
b. Shooting 
c. Burning 
d. Electric-like 
e. Stabbing 
f. Pins and needles
g. other____________________________
3 F. Is the discomfort in your hands worse after getting chemo? (circle one)
 a.   No  
 b.   Yes, for how many days ______
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4 A. Since starting chemotherapy, have you had discomfort in your feet (circle one)?
a. No   (go to the next page)   
b. Yes   (answer the questions below)
4 B. At its worst, how severe is the discomfort in your feet? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 4 C. At its worst, how distressing is the discomfort in your feet? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
4 D. How often do you have the discomfort in your feet? (circle one)
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
4 E. Circle the words that describe the discomfort in your feet? (circle as many as 
apply)
a.   Sharp 
b.   Shooting
c.   Burning 
d.   Electric-like 
e.   Stabbing 
f.    Pins and needles 
g.   other_______________________________
4 F. Is the discomfort in your feet worse after getting chemo? (circle one)
a. No     
b. Yes, for how many days? ______
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5 A. Since starting chemotherapy, have you developed sensitivity to cold 
temperatures? (circle one)
a. No   (go to the next page)   
b. Yes   (answer the questions below)       
5 B. What part(s) of your body are sensitive to cold? (circle as many as apply)
a.  Hands   
b.  Feet
c.  Throat   
d.  Jaw  
e.  Mouth
f.   Whole body
    
5 C.  At its worst, how severe is the cold sensitivity? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 5 D. At its worst, how distressing is the cold sensitivity? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
5 E. How often do you have the cold sensitivity? (circle one)  
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
5 F. Is the cold sensitivity worse after getting chemo? (circle one)
a. No     
b. Yes, for how many days ______
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6A. Since starting chemotherapy, have you developed muscle or joint aches? (circle 
one)
a. No (go to the next page)
b. Yes (answer the questions below)     
6B. What part(s) of your body ache? (circle as many as apply)
a. Muscles 
b. Joints 
c. Both muscles and joints
6 C. At its worst, how severe is the aching? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 6 D. At its worst, how distressing is the aching? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing                                     
6 E. How often do you have aching? (circle one)  
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
6 F. Is the aching worse after getting chemo? (circle one)
a. No     
b. Yes, for how many days _____
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7A. Since starting chemotherapy, have your arms or legs felt weak? (circle one)    
a. No    (go to the next page)
b. Yes    (answer the questions below)       
7B. What part(s) of your body have felt weak? (circle as many as apply)
a. Arms
b. Legs  
c. Both arms and legs
    
7 C. At its worst, how severe is the weakness in the arms or legs? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 7 D. At its worst, how distressing is the weakness in the arms or legs? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
7 E. How often do you have weakness in the arms or legs? (circle one)  
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
7 F. Is the weakness in the arms or legs worse after getting chemo? (circle one)
a. No     
b. Yes, for how many days? ______
97
Appendix F(continued)
8A. Since starting chemotherapy, have you had trouble with your balance? (circle 
one)
a. No    (go to the next page)
b. Yes    (answer the questions below)   
    
8 B. At its worst, how severe is the trouble with your balance? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not              Moderately                                              Extremely 
At all                                                        Severe                                                       Severe
Severe
 8 C. At its worst, how distressing is the trouble with your balance? (circle one)
0             1             2             3             4             5             6             7             8             9             10
Not                          Moderately                                               Extremely                                                        
At all                                                     Distressing                                              Distressing  
Distressing
8 D.  How often do you have trouble with your balance?  (circle one)
0             1             2             3             4             5             6             7             8             9             10
never                                                           50%                                                        always 
                                                    of the time
8 E. Have you had any falls since starting chemo?
a. No     
b. Yes,  describe ___________________________________________________
8 F. Do you use a cane or walker?
a. No 
b. Yes, I used a cane or walker before I started chemo 
c. Yes,  I started using a cane or walker since starting chemo
8G. Is the loss of balance worse after getting chemo? (circle one)
a. No     
b. Yes, for how many days ______
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If you answered yes to any of the previous symptoms, how much are your symptoms 
interfering with:
9 A. Dressing (buttoning, zipping, etc)   0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 B. Walking                                           0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 C. Picking up objects                            0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 D. Holding onto objects                      0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
                                               
9 E. Driving                                             0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                    Completely
                                                                             At all                           Interfering                        Interfering                      
                                                                             Interfering
9 F. Working                                            0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 G. Participating in hobbies                    0     1      2      3       4        5        6       7      8       9       10
         or leisure activities                               Not                           Moderately                      Completely
                                                                             At all                           Interfering                         Interfering                      
                                                                             Interfering
                                                                  
9 H.  Exercising                                       0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
             
9 I. Sleeping                                             0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
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9 J. Relationships with other people       0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
  
9 K. Writing                                            0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 L. Usual household chores                   0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
9 M. Enjoyment of life                            0     1      2      3       4        5        6       7      8       9       10
                                           Not                           Moderately                     Completely
                                                                             At all                           Interfering                       Interfering                      
                                                                             Interfering
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